Modulation of Ca2+ signaling by polyphenols in malignant mesothelioma cells by Ribulla, Stefania





DiSIT-Dipartimento di Scienze e Innovazione Tecnologica 




Modulation of Ca2+ signaling by 







Tutor:                                                 Ph.D. Student: 
Prof. Bruno Burlando                              Dott.ssa Stefania Ribulla 






Prof. Giorgio Malacarne 
	   1 
Table of contentents 
 
Abbreviations and Acronyms.................................................................      3 
 
Introduction…………………………………………………………….      6 
Disease definitions…………………………………………………      6 
Historical outline…………………………………………………..       7 
Disease etiology……………………………………………………      8 
Asbestos………………………………………………………      8 
SV40………………………………………………………….      10 
Genetics………………………………………………………      10 
Radiation……………………………………………………..      10 
Epidemiology……………………………………………………...      12 
MPM in Italy………………………………………………………      14 
Molecular pathogenesis of MPM………………………………….      17 
Clinical features and diagnosis…………………………………….      22 
Currently established therapy……………………………………...      24 
Surgery……………………………………………………….      25 
Chemotherapy………………………………………………..      26 
Radiotherapy…………………………………………………      26 
Multimodal approaches……………………………………....     27 
Novel therapies…………………………………………………….     28 
Tyrosine kinase inhibitors……………………………………      28 
	   2 
Therapy targeting cell-surface receptors……………………       28 
Immune checkpoint inhibitors………………………………       29 
Gene therapy………………………………………………..        29 
Immunotherapy and vaccines……………………………….       30 
Direct physical cytotoxic therapies…………………………        30 
Cancer chemoprevention using natural products………………...        32 
Natural products as treatment in MPM…………………………..        34 
 
Aims…………………………………………………………………..         35 
 
References……………………………………………………………         38 
 
Oleuropein-enriched olive leaf extract affects calcium  
dynamics and impairs viability of malignant mesothelioma cells...         50    
 
Resveratrol induces intracellular Ca2+ rise via  
T-type Ca2+ channels in a mesothelioma cell line…………………..         60   
 
Conclusions…………………………………………………………...         85 
 
References…………………………………………………………….         87 
 
Acknowledgements…………………………………………………...         88 
 
 
	   3 
Abbreviations and Acronyms 
 
AA: Ascorbic Acid 
Akt: also known as Protein Kinase B (PKB)  
AND therapy: Active Nutrients/Drug therapy  
BCA: Bicinchoninic Acid 
 [Ca2+]i: Cytosolic Ca2+ concentration	  	 
CAD: Collision activated dissociation gas 
Calcein-AM: Calcein-acetoxymethylester  
CT: Computerized tomography  
CTLA-4: Cytotoxic T lymphocyte antigen-4 
DM-4: Drug maytansinoids 
 
DMEM: Dulbecco's Modified Eagle's Medium  
DMSO: DiMethyl SulfOxide 	 
DNA: deoxyribonucleic acid 
 
EDTA: EthyleneDiamineTetraacetic Acid  
EGCG: EpiGalloCathechin-3-Gallate 
EGF: Epidermal Growth Factor 
EGFR: Epidermal Growth Factor Receptor 	 
EPP: Pneumonectomy 
ERK: Extracellular signal–regulated kinase   
FBS: Foetal Bovine Serum  
FDG: fludeoxyglucose F 18 
 
Fura-2AM: Fura-2-acetoxymethyl ester 
 
H&E stain: Hematoxylin & eosin stain 	 
HGF:	 Hepatocyte growth factor 
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HMGB1: High-mobility group box 1 
HT: Hydroxythyrosol 
IARC: International Agency for Research on Cancer  
IC50: half maximal Inhibitory Concentration 
ICD: International Classification of Disease 	 
IGF: Insulin-like growth factor 
IL-4-6-8: Interleukin 4-6-8 
INF: Interferon 
IPV: inactivated poliovirus vaccine 	 
LC/MS: Liquid chromatography–mass spectrometry 
  
MAP kinase or MAPK: Mitogen-Activated Protein Kinase  
MM: Malignant Mesothelioma  
MPM: Malignant Pleural Mesothelioma 
MPF: megakaryocyte potentiating factor 
MRI: Magnetic resonance imaging  
MTT: 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide 
 




PBS: Phosphate Buffered Saline 
P/D: pleurectomy/decortication  
PDGF: Platelet Derived Growth Factor  
PD-L1: Programmed death ligand 1 
PDT: Photodynamic Therapy  
PET: Positron emission tomography 
PMSF: Phenyl-methylsulfonyl fluoride 
Rb: retinoblastoma 
ReNaM: National Mesothelioma Register 
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Res: Resveratrol 
ROS: Reactive Oxygen Species  
siRNA: Small interfering RNA 
SMRP: Soluble mesothelin related protein 
SV-40: Simian Virus 40 	 
TGF-β: Transforming growth factor beta 
TIS: Turbo ion spray 
TLC: Thin Layer Chromatography 
 
TNF-α: Tumor Necrosis Factor-α 
TNM: Tumor node metastasis 
TP53: Tumor protein p53  
VATS: Video assisted thoracoscopic surgery  
VEGF: Vascular Endothelial Growth Factor  





















Malignant Mesotheliomas (MM) are, by definition, tumors that arise from mesothelial cells of 
any body cavity: pleura, peritoneum, pericardial sac, and tunica vaginalis testis. Malignant 
pleural mesothelioma (MPM) is the most common of these, accounting for approximately 




Figure 1. Normal and diseased pleura 
 
 
The risk of MPM is attributable to asbestos exposure, and has been reported to range between 
86% and 95% in most recent epidemiological studies (2-4). 
The estimated rate of non-asbestos-related MPM varies widely among studies and is allegedly 
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HISTORICAL OUTLINE 
There is clear evidence of asbestos use among various cultures since ancient times (6). The 
word asbestos is derived from a Greek term meaning inextinguishable or unquenchable, a 
reference to its fire-resistant properties (1). 
Heat resistant and insulating properties made asbestos a valuable commodity, particularly as 
the industrial revolution began. In the USA, mining and subsequent use of asbestos increased 
steadily during the first half of the 20th century, escalated rapidly following World War II, and 
peaked in 1973, after which it precipitously declined. 
Asbestos was widely used for the insulation of water and combustion pipes, as material for 
house construction and shipbuilding, as car brakes and gaskets, or in the manufacture of toys, 
jewellery, and cigarette filters. At the peak of asbestos use in industrial activities, about 3000 
asbestos-containing products were registered (7). 
The first report of a pleural tumor occurred in 1767 by Joseph Lieutand, the founder of 
pathologic anatomy in France, who in a study of 3000 autopsies found two cases of “pleural 
tumors”. Thereafter, mesothelioma was characterised as a specific disease by Klemperer and 
Rabin in 1931 (8). It took almost a further 30 years for mesothelioma to become widely 
accepted as a separate cancer entity. The definitive epidemiological study linking 
mesothelioma to asbestos came from South Africa, and was published in 1960 by J.C. 
Wagner, C.A. Sleggs and P. Marchand. These authors showed that mesothelioma was very 
prevalent in people living or working in crocidolite asbestos mine areas (9). Subsequently, 
several studies from the USA, Europe, Australia and Japan verified asbestos inhalation as the 

















The association of mesothelioma with asbestos exposure is well established, with an 
etiological fraction above 80% (13). 
This tumor was once rare, but its incidence has been increasing in several countries because 
of widespread exposure to asbestos in the past, and it is predicted that it will increase in the 
next decades, especially in developing countries where asbestos has not yet been banned for 
use (14). 
Asbestos refers to a group of crystalline-hydrated silicate minerals and is classified into two 
main families, the serpentines and the amphiboles (Tab. 1). The serpentines consist of 
chrysotile, consisting of short, curly fibres. This mineral is called “white asbestos”, due to its 
color, and accounts for 95% of marketed asbestos (15). The amphiboles, with straight, longer 
fibres, include crocidolite or “blue asbestos”, amosite, tremolite, actinolite and anthophyllite 
(16) (Fig. 2). 
Mixtures of chrysotile and amphiboles were used to produce an array of roofing, insulation 
and fire-proofing materials. 
Evidence exists that all types of asbestos fibres induce pulmonary toxicity in a dose-
dependent manner. Moreover, all fibre types possess carcinogenic potential; however, 
exposure to amphibole fibres, rather than to chrysotile, is more likely to cause mesothelioma 
(17). The association between amphibole asbestos exposure and MPM development is well 
known. In particular, crocidolite is considered the most carcinogenic type of asbestos. 
Erionite, an asbestos-like mineral, also causes MPM. 
Evidence suggesting a link between asbestos exposure and MPM insurgence has been deemed 
sufficient by the World Health Organisation (WHO) to conclude that all types of asbestos 
cause cancer in humans (18). 
The median latency between asbestos exposure and disease onset is 44.6 years, and it tends to 
increase over time in a linear fashion. Therefore, despite asbestos banning, incidence rates in 
Europe are still rising, with a peak expected around 2020 or beyond (19).  
There is some evidence that disease latency has an inverse relationship with the duration or 
degree of asbestos exposure (20).  
Although short or low-level asbestos exposures have been linked to the development of 
mesothelioma, the risk of disease demonstrates dose dependence (21). However, it has been 
shown that other etiologic factors have a role in MPM pathogenesis. 






Table 1. Composition and characteristics of asbestos fibers. Chrysotile is a hydrated magnesium silicate. The amphiboles 






                    
 
 
Figure 2. Scanning electron micrographs contrast curved fibers of chrysotile asbestos (left) with straight fibers of 
crocidolite (center) and amosite (right; bar=3 mm). Typically, chrysotile fibers exhibit a curved, curly, or wavy morphology, 
which is most apparent in fiber bundles exceeding 10 mm in length. In addition, the ends of chrysotile fiber bundles often 
exhibit a splayed appearance because of the separation of individual fibrillar units. This curly morphology influences the 
interceptive deposition of chrysotile fibers, which in turn, affects the depth of penetration into the lower respiratory tract. The 
diameters of individual fibers vary considerably with substantial overlap among members of the amphibole group. However, 








deaths predicted from this neoplasm.8)  This article brie!y reviews the history, epidemiology, and 
genomic analysis of human DMM, and discusses the possible molecular mechanisms underlying 
asbestos-induced carcinogenesis.
Asbestos !bers
Asbestos is a naturally occurring mineral conventionally divided into two mineralogic groups. 
The amphiboles include crocidolite (blue asbestos), amosite (brown asbestos), tremolite, anthophyl-
lite, and actinolite.  Among the amphiboles, only crocidolite and amosite have widespread 
commercial utilization.  The noncommercial amphiboles (the most commonly occurring and 
widely distributed amphibole asbestos mineral group) are primarily signi"cant as contaminants 
of other minerals, such as chrysotile.9)  The second group of asbestos minerals is the serpentine 
group, of which chrysotile (white asbestos) is the sole variety.  
The amphibole and serpentine minerals occur both as asbestiform ("brous) and nonasbestiform 
(massive) varieties of identical chemical composition.  Amphibole crystallization is believed to 
occur initially as the massive form under conditions of moderate temperature and pressure, with 
transformation into the "brous form occurring when the unstable massive form is submitted to 
rock stresses.  Similarly, serpentine minerals "rst crystallize as the massive form, with chrysotile 
being subsequently formed by recrystallization.10)  
Chrysotile is a hydrated magnesium silicate with the chemical composition indicated in Table 
1.  Individual "brils of chrysotile have diameters of 20–40 nm.  Crushing of chrysotile ore 
produces "ber bundles consisting of variable numbers of aggregated individual "brils.  These 
Table 1 Composition and characteristics of asbestos "bers
Name Composition Source Morphology
Chrysotile Mg6Si4O10(OH)8 U.S. and Canada Curly, pliable
Crocidolite Na2(Fe3+)2(Fe2+)3Si8O22(OH)2 South Africa
Western Australia
Rodlike, durable
Amosite (Fe, Mg)7Si8O22(OH)2 South Africa Rodlike, durable
Anthophyllite (Mg, Fe)7Si8O22(OH)2 Finland Rodlike, durable
Tremolite Ca2Mg5Si8O22(OH)2 Exists in some deposits of 
Canadian chrysotile
Rodlike, durable
Actinolite Ca2(Mg, Fe)5Si8O22(OH)2 Not mined Rodlike, durable
Fig. 1 Scanning electron micrographs contrast curved "bers of chrysotile asbestos (left) with straight "bers of 
crocidolite (center) and amosite (right; bar=3 m).  Asbestos "bers are from UICC.
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SV40 
The DNA virus, Simian Virus 40 (SV40), has been suggested as a causal co-factor of MPM 
insurgence (1). The most likely route of SV40 transmission from monkey to human was 
through SV40-contaminated polio vaccines that were produced between 1955 and 1978 (23). 
The first inactivated poliovirus vaccine (IPV) and live oral poliovirus vaccine were prepared 
in primary cell cultures derived from rhesus monkey kidneys. Studies of these vaccines led to 
the discovery of the DNA virus SV40 in 1959, a virus endemic in rhesus monkeys (24).  
SV40 contributes to the transformation of human cells by perturbing several intracellular 
pathways, including p53 and retinoblastoma (Rb) tumour suppressor pathway disabling (25). 
The strong and consistent relationship between experimental SV40 infection and cancer 
development in rodents motivated the investigation of its carcinogenic potential in humans. 
The interpretation of the repeated finding of SV40 in human tumors is still controversial and 
its role in overall human mesothelioma incidence remains unclear (26). However, recent 
studies showed that animals infected or transfected with SV40 were extremely susceptible to 
asbestos carcinogenesis, and these techniques are currently used as an in vivo model to study 




Observation of high MPM rates in the Cappadocian villages of Turkey has identified other 
potential etiological factors. Genetic susceptibility to MPM was observed in the Cappadocian 
villages of Tuzkoy, Karain, and ‘‘Old’’ Sarihidir. Although mineralogical studies showed that 
all the buildings of these villages contained similar amounts of erionite, MPM was prevalent 
in certain families but not in others. Pedigree studies of the three MPM villages showed that 
the tendency to develop MPM seemed to be inherited in an autosomal dominant pattern. 
Genetically predisposed family members born and raised outside the MPM villages did not 
seem to develop MPM, supporting the observation that the combination of genetics and 





Long-term effects of ionizing radiations have been etiologically linked to MPM, although in a 
much smaller group of individuals compared to those exposed to asbestos. Several case 
reports have documented MPM in patients who had received therapeutic radiation to the 
	   11 
thorax or abdomen (29). The average interval between exposure to radiations and MM 
diagnosis was 21 years (30). Animal studies using rats also suggest the role of radiation as a 
causative factor of MPM. 
It is also well documented that MPM is over-represented in testicular cancer and Hodgkin’s 
lymphoma survivors who have been treated with external radiotherapy (31,32). However, due 
to improved knowledge on secondary cancer formation and the introduction of alternative 
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EPIDEMIOLOGY 
MPM incidence is variable within and between countries because of differences in asbestos 
use (33). MPM was extremely rare until the second half of the 20th century. Since then, the 
incidence of MPM has increased significantly, in association with widespread use of asbestos. 
Currently, there are about 2000 to 3000 cases per year in the United States (34) and an 
additional 5000 deaths in Western Europe (35).  
Overall, except Australia and USA, incidence of MPM is expected to peak between 2015 and 







Table 2 Predicted peak incidence years and incidence at peak for mesothelioma in various countries (37). 
 
 
The WHO estimates that at least 125 million people globally are occupationally exposed to 
asbestos. Based on the International Agency for Research on Cancer (IARC), a total of 
120,544 new cases of MM were reported during the period 1988-2002, with 58% of these 
cases from North America, 33% from Europe, 5% from Oceania, and 3% from Asia (38).  
However, the planetary occurrence of MM is likely to be underestimated, owing to unreported 
cases in mortality registries of developing countries (39), inaccurate death certification 
(40,41), and undifferentiated International Classification of Diseases (ICD) codes for pleural 
malignancy until 1994 (42). The latency period, i.e. the interval between first exposure and 
the development of MPM, ranges between about 25-71 years (43).  
Moreover, analysis of MPM trends in different countries revealed a significant annual 
increase in Japan (3.5%) and a decrease in the United States (0.84%) (44) suggesting that 
disease burden is slowly shifting toward countries that have used asbestos more recently. The 
delayed peak in Japan can be correlated to the historical delay in heavy asbestos usage (45). 
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MPM is a less common disease in women (with a male to female ratio of 3.8:1) (38). 
Approximately 80% of patients who develop MPM are men (46). 
The disease can occur in any age group but is more common in 6th decade and only about 2% 
to 5% of cases are reported in the first two decades of life (47). The median age at the 
diagnosis of MPM is 72–74 years (48,49).  
Given the role of asbestos in the etiology of MPM, three waves of disease occurrence have 
been described (50). The first affected miners and millers employed in the extraction of raw 
asbestos and in the manufacture of asbestos products. A second wave of disease became 
evident in workers who used asbestos products in industry, such as carpenters, plumbers, 
defence personnel, shipbuilders, and insulation installers. The third wave of disease included 
people with unknown, short-term, or low-level exposure to asbestos. Examples of these kinds 
of exposures, frequently non-occupational ones, include domestic (relatives of asbestos 
workers), air pollution from nearby asbestos industry, and exposure to asbestos in place 
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MPM IN ITALY 
In a period going from the 1950’s to total national banning in 1992, Italy was an important 
producer and user of asbestos and asbestos-containing materials. Up to the end of the 1980’s 
Italy was the second largest asbestos producer in Europe, after the Soviet Union, and the 
largest in the European Community. 
In particular, asbestos production reached a peak in the 1976–1980 period, but remained 
steadily over 100,000 tons/year until 1987. These temporal patterns made the peak in asbestos 
consumption to occur later on in Italy with respect to other European countries and the United 
States (52). Therefore, considering the long latency of MPM (generally around 35–40 years 
from first exposure), a high number of cases is still expected in Italy in the next few decades 
(53). 
Because of its previous high utilization, the wide spectrum of industries involved and the 
number of workers and non-workers exposed, Italy is among those countries that are most 
prone to adopt measures for preventing asbestos related diseases. In addition, Italy has a 
specific system for mesothelioma epidemiological surveillance: the National Mesothelioma 
Register (ReNaM), active since 2002 and operating through a regional structure. The registry 
currently holds data about cases of malignant mesothelioma between 1993 and 2008, 
concerning subjects resident in Italy. Data from cases diagnosed between 2009–2013 are 
currently under acquisition (54).  
In the period 1993-2008, 15,322 incident cases of all-site MM were recorded. Most MM cases 
(93%) occurred in the pleural site. Standardised incidence rates for pleural mesothelioma in 
2008 were 3.84 per 100,000 for men and 1.45 for women, respectively. Among the 15,845 
mesothelioma cases, exposure to asbestos fibres was assessed for 12,065 individuals (76.1%), 
identifying 530 (4.4%) with familial exposure (they lived with an occupationally exposed 
cohabitant), 514 (4.3%) with environmental exposure to asbestos (they lived near sources of 
asbestos pollution and were never occupationally exposed) and 188 (1.6%) exposed through 
hobby-related or other leisure activities. (Tab. 2). Clusters of cases due to environmental 
exposure are mainly related to the presence of asbestos-cement industry plants (Casale 
Monferrato, Broni, Bari), to shipbuilding and repair activities (Monfalcone, Trieste, La 
Spezia, Genova) and soil contamination (Biancavilla, Sicily) (55). (Fig. 3). The mean age at 
diagnosis was 69.3 years with no significant difference by gender (70.3 for women and 68.9 
for men). Less than 10% of cases occurred in subjects younger than 55 years.  
 
 





Table 2. Incident cases of malignant mesothelioma recorded by the Italian national mesothelioma registry (ReNaM) 









uncorrected standardized incidence ratios and of distri-
bution of posterior probability of the estimated RR
exceeding 1 for all areas are reported in Additional files
1, 2, 3, 4, 5, 6, 7 and 8.
The distribution of cases in the clusters by gender and
by geographic area, as well as the environmental fraction
of cases (i.e. the percentage of cases attributed to envir-
onmental exposure to asbestos based on expert evalu-
ation of the information collected through interviews)
and the size of unrecognized exposures among defined
cases are shown in Table 2. Table 3 reports detailed in-
formation about asbestos exposure referring to the main
economic activities involved, i.e. those causing more
than 3% of defined MM cases in each cluster. For several
large clusters less represented economic sectors (less
than 3%) also need to be mentioned. A significant num-
ber of MM cases was attributable in the Genoa cluster
to military defense (N = 28), an oil refinery (N = 19) and
an electric power plant (N = 13), and in the Trieste cluster
to many wood furniture factories (N = 14), a steel industry
Table 1 Incident cases of malignant mesothelioma recorded by the Italian national mesothelioma registry (ReNaM)
selected for the cluster analysis
Men Women
Number of cases % Number of cases %
Age class 0-54 1,046 9.6 450 10.3
55-64 2,646 24.1 856 19.7
65-74 4,015 36.6 1,404 32.2
75+ 3,257 29.7 1,648 37.8
Period of diagnosis 1993-1996 1,042 9.5 382 8.8
1997-2000 2,271 20.7 884 20.3
2001-2004 3,706 33.8 1,503 34.5
2005-2008 3,945 36.0 1,589 36.4
Area Northwest 5,158 47.1 2,423 55.6
Northeast 2,586 23.6 901 20.7
Centre 1,450 13.2 454 10.4
South & Islands 1,770 16.1 580 13.3
Diagnostic certainty Definite 8,708 79.4 3,234 74.2
Probable 1,142 10.4 574 13.2
Possible 1,114 10.2 550 12.6
Site of lesion Pleura 10,312 94.0 3,941 90.4
Peritoneum 579 5.3 403 9.3
Pericardium 26 0.2 14 0.3
Testis 47 0.4 - -
Exposure ascertainment Direct interview 4,585 41.8 1,401 32.2
Indirect interview 4,139 37.8 1,727 39.6
No interview 2,240 20.4 1,230 28.2
Type of exposure Occupational, definite 4,987 45.5 526 12.1
Occupational, probable 890 8.1 112 2.6
Occupational, possible 1,291 11.8 402 9.2
Familial 76 0.7 446 10.2
Environmental 214 1.9 294 6.7
Other non-occupational 80 0.7 108 2.5
Unlikely 193 1.8 223 5.1
Unknown 993 9.1 1,017 23.3
Undefined 2,240 20.4 1,230 28.2
Total 10,964 4,358
Italy, 1993–2008 (N = 15,322).
Corfiati et al. BMC Cancer  (2015) 15:286 Page 4 of 14








Figure 3. Crude incidence rates of malignant mesothelioma (MM) cases by Italian municipalities. Italian National 
Mesothelioma Register (ReNaM). Italy, men and women, 1993–2008. Diagnosis of MPM definite, probable or possible, 
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MOLECULAR PATHOGENESIS OF MPM 
MPM develops insidiously in patients who are usually diagnosed at advanced stages, because 
radiological diagnostic tools are not effective for early detection, while early serum 
biomarkers have not been established yet. The anatomical location and characteristics of the 
body cavities where MPM initially develops also cause malignant cells to easily spread and 
invade tissues.  
Pathologically MPM is subdivided into three major subtypes, viz. epithelioid, sarcomatoid, 
and biphasic, the latter showing both epithelioid and sarcomatoid components (57).  
MPM subtypes differ in their morphology, biological/clinical phenotypes, aggressiveness and 
response to treatment (58). 
The epithelioid MPM consists of cuboidal or polygonal cells with abundant cytoplasm and 
uniform round nuclei forming a tubular and papillary pattern. The sarcomatoid MPM consists 
of sheets or fascicles of spindle cells of variable cellularity and pleomorphism. According to 
the World Health Organization, biphasic MPM must contain at least 10% epithelial and at 
least 10% sarcomatoid patterns (59). Epithelioid is the most common sub-type among MPM 


























Figure 4. Histologic types of MPM. Microphotograph (H&E stain) of epithelioid mesothelioma (A), sarcomatoid 




The antibodies chosen for sarcomatoid mesothelioma
are very different from those used for epithelioid meso-
thelioma. In the case of sarcomatoid mesothelioma,
cytokeratin (AE1/AE3 or CAM5.2 as antibodies) exhibits a
high specificity and is the most useful [24]. On the other
hand, because the diagnosis for true sarcoma is based on
the specific differentiation of tumor cells, mesothelioma is
eliminated by making its differentiation clear. For example,
the following antibodies are known to be useful: MyoD1,
desmin and myoglobin for rhabdomyosarcoma; desmin, a-
SMA and h-caldesmon for leiomyosarcoma; S-100p for
malignant nerve sheath tumor; KP-1 for malignant fibrous
histiocytoma [25].
The most difficult tumor to be differentiated from sar-
comatoid mesothelioma of pleura is sarcomatoid
carcinoma (spindle cell carcinoma, pleomorphic carci-
noma) of the lung. When immunohistochemical stainings
are used, both respond positively to cytokeratin [24]. In this
case, therefore, the gross finding or the clinical diagnosis
by imaging is very important, as already mentioned.
Immunohistochemical stains may be useful in differen-
tiating between fibrous pleuritis and desmoplastic
mesothelioma. Desmin is positive for spindle cells of the
fibrous pleuritis, while desmin is negative for tumor cells of
the sarcomatoid mesothelioma [26]. The combination of
EMA, desmin and p53 is useful for differentiating between
reactive mesothelial hyperplasia and early-stage epithelioid
mesothelioma. Reactive mesothelial cells are positive for
desmin and negative for EMA and p53 [27].
Compensation or relief of patients
In the compensation system for occupational exposures to
asbestos and in the new law for non-occupational exposure
to asbestos, if the diagnosis of mesothelioma is certain, it
Fig. 4 Microphotograph of desmoplastic mesothelioma (H&E stain).
The feature of granulation or fibrous pleuritis are dominant
Fig. 1 Microphotograph of epithelioid mesothelioma (H&E stain).
Papillo-tubular structure is prominent
Fig. 2 Microphotograph of sarcomatoid mesothelioma (H&E stain).
Proliferation of spindle cells mimies true sarcoma
Fig. 3 Microphotograph of biphasic mesothelioma (H&E stain). The
features of epithelioid mesothelioma and that of sarcomatoid meso-
thelioma are mixed within one tumor
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The exact mechanisms of mesothelioma pathogenesis are unknown. However, several recent 
MM reviews report comprehensive lists of genetic, epigenetic and signaling alterations (62). 
A main mechanism is thought to be triggered by asbestos fiber penetration within the lung 
tissue. When long and thin asbestos fibers are inhaled deeply into the lung and penetrate the 
pleural space, they start to interact with mesothelial cells and inflammatory cells. (Fig. 5). 
This is thought to trigger prolonged cycles of damage/repair in lung tissue, accompanied by 










Alternative routes of fiber translocation to the parietal pleura include lymphatic and 
haematogenous dissemination (17). The exact way in which asbestos fibers cause these 
changes is uncertain, but researchers believe such changes are responsible for cancer 
development. It also remains unclear why the initial affected site of MPM development by 
asbestos exposure is the parietal instead of the visceral pleura. Compared with other cell 
types, human mesothelial cells are very susceptible to asbestos cytotoxicity, which raises a 
paradoxical issue of how asbestos causes MPM if human mesothelial cells exposed to 
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asbestos die (64). It is however known that several features of asbestos fibers contribute to 
their carcinogenicity, including chemical composition, fibers length and form, and their 
biopersistence (65). It has been also shown that asbestos has pleiotropic effects on cell 
signaling pathways (66, 67). (Fig. 6). First, reactive oxygen species generated by asbestos 
fibers lead to DNA damage and strand breaks (68-70). Second, macrophages that phagocyte 
asbestos fibers are unable to digest them, resulting in further production of reactive oxygen 
species (70). These events activate MAP-kinase signaling pathways through the epithelial 
growth factor (EGF) receptor, which is frequently highly expressed in mesothelioma together 
with downstream transcription factors. 
The long latency period of the disease (up to 40 years) suggest that multiple genetic 
alterations are important in the conversion from normal to malignant mesothelial cell. 
Comprehensive karyotypic analysis has revealed that malignant mesotheliomas display 
multiple clonal chromosomal abnormalities (more than 10 of them in most cases). This can be 
explained by considering that asbestos fibers engulfed by mesothelial cells can physically 
interfere with the mitotic process of the cell cycle, thereby damaging the mitotic spindle. This 
may result in chromosomal structural abnormalities and aneuploidy of mesothelial cells (71).  
The loss of one copy of chromosome 22 is the most typical single chromosomal change in 
patients with mesothelioma. Specific deletions of chromosomal sites involve the short arm (p) 
of chromosomes 1, 3 and 9, as well as the long arm (q) of chromosome 6. Other non-random 
cytogenetic alterations have been detected on other chromosomes (72). Mutations of the p53 
gene (TP53) are occasionally observed in MPM (73). Loss and/or inactivation of tumor 
suppressor genes like TP52 may play a role in the development and progression of MPM. 
Asbestos fibers can absorb chemicals to their surface, with the consequent accumulation of 
hazardous molecules (including carcinogens). Fibers can also bind cellular proteins, possibly 
leading to detrimental deficiency for normal mesothelial cells (74). Finally, asbestos-exposed 
mesothelial cells and macrophages release a variety of cytokines and growth factors, 
including inflammation and tumor promotion agents like transforming growth factor beta 
(TGF-β), which might have a role in stimulating tumor growth; platelet-derived growth factor 
(PDGF), which may act as a regulatory factor in MM cell proliferation, insulin-like growth 
factor (IGF), which promotes tumor proliferation and cell migration (75); interleukins such as 
IL-6 and IL-8, which may promote tumor growth and the development of new capillaries 
(76); vascular endothelial growth factor (VEGF), which also promotes tumor angiogenesis 
(77), and hepatocyte growth factor (HGF), which stimulates mesothelioma cell migration and 
invasiveness (78). 
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Tumor necrosis factor-α (TNF-α ) has been shown to activate nuclear factor-κB (NF-κβ), 
which leads to mesothelial cell survival and inhibits asbestos-induced cytotoxicity (79, 80). 
High-mobility group box 1 (HMGB1) protein is also released from mesothelial cells, which 
are exposed by asbestos and then undergo necrotic cell death, promoting an inflammatory 












Figure 6. Possible mechanisms of asbestos-induced carcinogenesis. HMGB1, high-mobility group box 1 protein; ROS, 
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CLINICAL FEATURES AND DIAGNOSIS 
Clinical MPM symptoms are usually atypical and nonspecific. The most common one is 
dyspnea (90% of cases) that is typically caused by pleural effusion. Commonest initial 
symptoms are pain (35%) caused by irritation of intercostal nerves or by infiltration into the 
chest wall, distension of abdomen (31%), and less frequently night sweats. Patients also 
commonly develop cachexia, anorexia or ascites (77%) (47). Weight loss is a late sign of 
disease, along with generalized malaise and failure to thrive (82). Rarely, patients present 
with fever of unknown origin, intestinal obstruction or acute abdominal surgical emergency. 
Symptomatic metastases are unusual. In addition, the majority of patients report late due to 
very elusive and atypical symptoms, leading to diagnostic delays of up to six months (83). 
Considering the elusive nature of the disease, the diagnosis of MPM should be considered in 
any patient with a unilateral pleural effusion or thickening, especially if chest pain is present. 
Whenever MPM is suspected, a detailed occupational history should be taken and the patient 
should be referred to an experienced center for pulmonary medicine.  
An important help to clinicians in this phase can be provided by imaging diagnostic tools, 
which also play an important role in staging, treatment planning (especially in terms of 
resectability), response assessment, and follow up of MPM patients. Initially, non-invasive 
tests such as ultrasonography, computerized tomography (CT), and magnetic resonance 
imaging (MRI) can be used to obtain further support for the suspected diagnosis and assess 
the extent of disease. CT is useful to judge the extent of tumor and to detect lymphonode 
metastases. MRI is the best way to determine whether the tumor has invaded the diaphragm or 
the chest wall. Positron emission tomography (PET) is also coming into wide use; its main 
advantage is a greater sensitivity for the detection of distant metastases (84). The integration 
of PET functional data coupled to radio-pharmaceutical FDG, with anatomical data from CT 
(PET/CT) could be useful in the diagnosis and preoperative staging of patients. (85).  
In order to render an accurate diagnosis, a biopsy sample must provide adequate diagnosable 
tissue. For the diagnosis of MPM, a biopsy sample typically is obtained form open procedures 
such as thoroscopy. Biomarkers would be helpful in managing three clinical aspects of MPM: 
early diagnosis, prognosis, and outcome prediction. Researchers have actively sought MPM 
biomarkers for more than 20 years. However, at present, there are no biomarkers in clinical 
use for MPM. In fact, MPM remains a rare disease and the small number of patients and the 
difficult accessibility to a uniform tumor population renders the search for biomarker 
frustrating. For early diagnosis, optimal serum biomarker for mesothelioma would predict 
mesothelioma development in asbestos-exposed subjects, differentiate mesothelioma from 
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benign pleural disease or metastatic cancer, could be useful for pathologic subtypes, and 
correlate with disease extent in order to monitor treatment response and predict prognosis. 
(86). The biomarkers osteopontin (87), soluble mesothelin-related protein (SMRP) (88), and 
megakaryocyte potentiating factor (MPF) are currently most promising for diagnosis, but each 
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CURRENTLY ESTABLISHED THERAPY  
Treatment options depend on multiple factors, including patient age, performance status, 
tumor histology, and disease stage at presentation. 
The staging system proposed by the International Mesothelioma Interest Group was accepted 
by the International Union Against Cancer and the American Joint Commission on Cancer 
(Tab. 3 and 4). This system describes the extent of tumor according to the tumor-node-
metastasis (TNM) classification, i.e. local extent of the primary tumor (T descriptor), presence 
and location of lymphnodes (N descriptor), and presence of distant metastatic disease (M 






Table 3. Staging Evaluation: TNM International Staging System for Diffuse MPM (92).  
 
 
mammary and anterior diaphragmatic lymph nodes. The
posterior diaphragmatic lymphatics drain into the para-aortic
and posterior mediastinal lymph nodes. There is communi-
cation between lymphatics on both sides of the diaphragm,
including the retrocrural, inferior phrenic, gastrohepatic, and
celiac regions. Extrathoracic metastatic disease has been seen
at autopsy in 50%-80% of cases.15 Distant hematogenous
metastases are common and can involve the lungs, liver,
spleen, adrenal glands, lymph nodes, bones, and brain.
Clinical Presentation
Patients with MPM usually present with slow onset of chest
pain, shortness of breath, and cough. Chest wall invasionmay
lead to intractable pain. Pleural effusion can be seen in up to
95% of cases. Tumor infiltration of the pleura may encase the
lung. Mediastinal invasion may lead to dysphagia, phrenic
nerve paralysis, cardiac tamponade, and superior vena cava
syndrome.
Differential Diagnosis
The radiologic manifestations of MPM include a unilateral
pleural effusion, a pleural mass or diffuse pleural thickening.
The differential diagnosis of a unilateral pleural effusion is
extensive, including congestive heart failure, infection, pul-
monary embolism, collagen vascular, and subdiaphragmatic
diseases. The differential diagnosis of a pleural mass includes
metastatic disease, sarcoma, lymphoma, and localized fibrous
tumor of the pleura. Localized fibrous tumors of the pleura
arise frommesenchymal cells, can be benign ormalignant, are
not related to asbestos exposure and have better prognosis
than MPM. The differential diagnosis of diffuse nodular
pleural thickening is limited and includes MPM, metastatic
disease, and in cases with a mediastinal mass, thymic
Table 1 Staging Evaluation: TNM International Staging System for Diffuse MPM
T—primary tumor
T1a tumor limited to ipsilateral parietal pleural, including mediastinal and diaphragmatic pleura
No involvement of visceral pleura
T1b tumor involving ipsilateral parietal pleura, including mediastinal and diaphragmatic pleura
Scattered foci of tumor also involving visceral pleura
T2 tumor involving each ipsilateral pleural surface with at least 1 of the following features:
! involvement of diaphragmatic muscle
! confluent visceral pleural tumor (including fissures) or extension of tumor from visceral pleura into underlying pulmonary
parenchyma
T3 locally advanced but potentially resectable tumor
Tumor involving all of ipsilateral pleural surfaces with at least 1 of the following:
! involvement of endothoracic fascia
! extension into mediastinal fat
! solitary, completely resectable focus of tumor extending into soft tissues of chest wall
! nontransmural involvement of pericardium
T4 locally advanced technically unresectable tumor
Tumor involving all of ipsilateral pleural surfaces with at least 1 of the following:
! Diffuse-extension or multifocal masses of tumor in chest wall, with or without associated rib destruction
! direct transdiaphragmatic extension of tumor to peritoneum
! direct extension of tumor to contralateral pleura
! direct extension of tumor to 1 or more mediastinal organs
! direct extension of tumor into spine
! tumor extending through to internal surface of pericardium with or without pericardial effusion, or tumor involving myocardium
N—lymph nodes
NX regional lymph nodes not assessable
N0 no regional lymph node metastases
N1 metastases in ipsilateral bronchopulmonary or hilar lymph nodes
N2 metastases in subcarinal or ipsilateral mediastinal lymph nodes, including ipsilateral internal mammary nodes
N3metastases in contralateral mediastinal, contralateral internal mammary, and ipsilateral or contralateral supraclavicular lymph
nodes
M—metastases
MX distant metastases not assessable
M0 no distant metastases
M1 distant metastases present
Malignant pleural mesothelioma 325




Table 4. Classification of Stage by TNM Description (92). 
 
 
The relatively low incidence of MPM poses a challenge to the evaluation of the effectiveness 
of treatment options because of difficulties in the accrual of patients in clinical trials, 
particularly large, randomized prospective trials. Given this limitation, the failure of single-
modality therapy, i.e. chemotherapy, radiation therapy, or surgery alone, has led to the 




The role of surgery in MPM treatment is still uncertain. In general, patients with stage I 
disease can be considered candidates for radical surgery. The three most common surgical 
procedures are debulking surgery (also known as cytoreductive surgery or 
pleurectomy/decortication (P/D)), extra pleural pneumonectomy (EPP), and surgical 
pleurodesis via video assisted thoracoscopic surgery (VATS). P/D is a lung-sparing operation 
in which the pleura is mobilized off the chest wall, mediastinum, diaphragm, and pericardium, 
and stripped from the surface of the lung. Pleurectomy has not been shown to prolong 
survival but can reduce the recurrence of pleural effusion better than talc pleurodesis (94). In 
contrast, EPP is the radical en bloc resection of the lung, visceral and parietal pleura, 
ipsilateral diaphragm, and adjacent pericardium (95). It is a rather complex operation, which 
should be performed by skilled surgeons and in selected centres. VATS is a type of thoracic 
surgery performed using a small video camera that is introduced into the patient's chest via a 
scope. It is a minimally invasive surgical technique used to diagnose and treat problems in the 
chest. Operations that were traditionally carried out with thoracotomy or sternotomy and are 
currently performed with VATS include: biopsy for diagnosis of pulmonary, pleural or 
malignancy with pleural metastases. CT features that aid in
differentiating malignant from benign pleural disease include
pleural thickening with a circumferential distribution encas-
ing the lung (sensitivity 100%, specificity 41%), pleural
thickening of greater than 1 cm in thickness (sensitivity
94%, specificity 36%), and nodular morphology (sensitivity
94%, specificity 51%).16
Staging
A clinically and pathologically accurate staging system is
essential in the selection of homogeneous groups of patients
with similar prognoses for entry into clinical trials to better
assess new treatment options. The staging system proposed
by the International Mesothelioma Interest Group was
accepted by the International Union Against Cancer and the
American Joint Commission on Cancer (Tables 1 and 2).17
This system describes he extent of tumor according to the
tumor-node-metastasis (TNM) classification that is, the local
extent of the primary tumor (T descriptor), the presence and
location of lymph node involvement (N descriptor), an the
presence of distantmetastatic disease (Mdescriptor). Recently,
the International Association for the Study of Lung Cancer
Staging Committee developed a large international d tabase
of 3101 patients from 15 centers on 4 continents to examine
outcomes in surgically managed MPM patients that suggest
the need to revise T and N staging.18 Initial nalysis of thi
database showed that significant differences in overall survival
were seen for: T4 vs T3 and T3 vs T2 but not T2 vs T1; N0 vs
N1 and N2 but not N1 vs N2; stages III and IV vs stage I but
not stage II vs stage I.
This analysis also confirmed the importance of distinguish-
ing patients who would benefit from surgical resection from
those needing palliative treatment. Limitations in staging
using imaging modalities such as CT, MRI, and PET and the
morbidity and mortality associated with surgical resection
have resulted in the need for extended surgical staging in
patients being considered for resection. Thus, cervical media-
stinoscopy or endobronchial ultrasound-guided lymph node
biopsy, laparoscopy and peritoneal lavage may be performed
in MPM patients undergoing preoperative evaluation for
aggressive multimodality therapy. Rice et al. reported that
extended surgical staging precluded 15 of the 118 patients
(12.7%) assessed by clinical staging alone to be candidates for
extrapleural pneumonectomy (EPP).19
Imaging is limited in determining the true extent of MPM.
When comparedwith surgical staging, CT has been shown to
underestimate the extent of disease in patientswith early chest
wall involvement, small positive lymph nodes, transdiaph-
ragmatic extension, peritoneal implants, and abdominal
organ metastases less than 2 mm in size.20 Despite these
limitations, CT is still the imaging modality of choice in the
initial staging and surveillance of patients withMPMdue to its
easy accessibility and cost-effectiveness.
T Staging
Accurate T staging is important in determining resect-
ability.17 In patients with locally advanced tumors,
imaging is usually aimed at distinguishing T3 disease (a
solitary focus of chest wall involvement, involvement of
the endothoracic fascia, mediastinal fat extension, or
nontransmural pericardial involvement) (Fig. 2) from
unresectable (T4) disease (diffuse tumor extension or
multiple chest wall foci, direct extension to the media-
stinal organs, spine, internal pericardial surface or con-
tralateral pleura, and transdiaphragmatic invasion).
However, the pathologic descriptors for T staging are
often difficult to determine on CT and MRI.
In locally advanced (T4) disease, the poor accuracy of
CTand MRI in detecting transdiaphragmatic extension of
MPM is due to their inability to identify microscopic
disease. Thus, preoperative laparoscopy and peritoneal
lavage are routinely performed in some institutions in
patients being considered for EPP. In the study by Rice
et al., l paroscopy identified 10 of 109 (9%) patients with
transdiaphragmatic invasion or peritoneal metastases
compared with 3 of 109 patients identified by cross-
sectional imaging.19
N Staging
The N descriptor denotes the presence and location of
lymph node involvement. Large retrospective studies
have sh wn intrathoracic nodal metastases in up to
50% of MPM patients who undergo radical resection.21
CT is typically used to evaluate for hilar and mediastinal
nodal disease and uses size of greater than 1 cm in short-
axis dimension as an indicator of suspicious nodal
disease. The specificity of CT for detecting nodal disease
is poor because metastases can be seen in nodes less than
1 cm in size whereas enlarged lymph nodes greater than
1 cm in size can be hyperplastic. Furthermore, it can be
difficult to differentiate hilar or mediastinal lymph nodes
from tumor involving the mediastinal pleura (Fig. 3).
Owing to the poor outcome of patients with extrapleural
nodal involvement who undergo radical resection, inva-
sive nodal sampling is important in patient selection.22
Schouwink et al. performed mediastinoscopy in 43
patients with MPM and compared the staging accuracy
with that of CT. Sensitivity, specificity, and accuracy were
80%, 100%, and 93%, respectively, for mediastinoscopy
compared with 60%, 71% and 67%, respectively, for CT.23
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mediastinal pathology, decortication, pleurodesis for recurrent pleural effusions or 
spontaneous pneumothorax, surgical stapler-assisted wedge resection of lung masses, and 
resection of mediastinal (96). The goal of surgery is gross total resection of the tumor. As 
mesotheliomas tend to grow diffusely, they are usually not totally resectable; some residual 
tumor tissue (often microscopic) is generally left behind. Adjuvant chemotherapy is therefore 




The use of chemotherapy in malignant mesothelioma aims to lengthen survival, improve 
quality of life and provide symptomatic relief. At present, there is no single drug or 
combination therapy that could be considered as a standard treatment for mesothelioma. 
Chemotherapy is the mainstay of therapy because of the fact that most MPM patients present 
with advanced disease. In a meta-analysis of studies published between 1965 and 2001, 
cisplatin was found to be the most active single drug, while its use in combination 
chemotherapy has been associated with higher response rates, but not with longer survival 
(98). Several new cytotoxic agents with definite activity in mesothelioma have recently been 
evaluated, including gemcitabine, imatinib, and the antifolates pemetrexed and raltitrexed. 
The pemetrexed/cisplatin combination significantly improved response rates, time to 




The role of radiation therapy in MPM is as controversial as the role of surgery. Radiotherapy 
can be used to control local MPM growth and occasionally causes regression of disease, but 
there is no evidence that radiotherapy alone affects survival (100). Patients with 
mesothelioma are given prophylactic radiotherapy at puncture sites and after surgical 
interventions to prevent local recurrence and to relieve pain in palliative care. Radical 
radiotherapy of the entire tumor is not currently feasible, because these tumors tend to grow in 
a complex geometrical configuration, and the resulting high radiation load of treatment would 
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Multimodal approaches 
Specialized mesothelioma centers employ multi-modality approaches, including surgical 
resection, chemotherapy, and radiation, with survival in excess of 20 months depending on 
stage (102). 
In a clinical trial, neo-adjuvant chemotherapy combined with pleuropneumectomy and 
followed by radiotherapy has led to a survival rate 3-year longer, on average, then those 
obtained with unimodal treatments (76 %) (103). In another study, multimodal approach has 
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NOVEL THERAPIES 
Many novel strategies are being attempted to improve survival for patients with MPM. 
Several classes of targeted therapies have emerged from preclinical work and are being 
evaluated. These treatments focus on the following broad mechanisms: 
 
• Tyrosine kinase inhibitors 
• Antibody conjugated toxins 
• Immune checkpoint inhibitors 
• Gene therapy 
• Tumor vaccines 
 
Tyrosine kinase inhibitors 
Molecular studies of mesothelioma specimens have shown marked overexpression of protein 
targets such as epidermal growth factor receptor (EGFR) and vascular endothelial growth 
factor (VEGF) (105).  
The inhibition of EGFR-dependent signaling pathway in mesothelioma cell lines leads to 
decreased cell survival (106); based on these findings, several clinical trials have been 
conducted but, disappointingly, these studies did not show improved survival.  
Higher levels of VEGF may be reflective of more-advanced disease and have been associated 
with shorter survival. In vitro studies have demonstrated that increased mesothelioma cell 
proliferation occurs upon treatment with VEGF and that significant inhibition of cell growth 
can be achieved by blocking this pathway (107). It is therefore thought that interference with 
this pathway could potentially lead to successful therapy. Numerous clinical trials have 
evaluated the effect of VEGF inhibitors alone and in combination with other drugs, but also 
the results of these trials have been disappointing. 
 
Therapy targeting cell-surface receptors 
Mesothelin is a 40-kDa, glycosylphosphatidylinositol-anchored cell-surface glycoprotein 
present on normal mesothelial cells and overexpressed on the surface of mesothelioma. 
Mesothelin overexpression, occurring more prominently on epithelioid tumors, may serve to 
alter cell adhesion and/or invasion. Preclinical studies in nude mice suggested that MORAb-
009 (amatuximab), a monoclonal antibody with high affinity for human mesothelin combined 
with chemotherapy (gemcitabine or paclitaxel) was more effective than either chemotherapy 
alone (108). BAY 94-9343 (anetuman ravtansine) is a human antimesothelin antibody 
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coupled via a reducible disulfide bond to DM4, a microtubule-targeting toxophore that shows 
highly selective cytotoxicity against cells with high mesothelin expression. Preclinical studies 
have shown a dose-dependent and receptor-dependent, 94% reduction of tumor growth with 
BAY 94-9343 compared to 70% reduction with cisplatin and pemetrexed (109). 
SS1P is an immunotoxin consisting of an antimesothelin antibody variable fragment linked to 
a cytotoxic fragment of Pseudomonas exotoxin A. Phase I trial including 16 mesothelioma 
patients has shown that SS1P was well tolerated up to 25 µg/kg/day × 10 days, with modest 
clinical activity and minor responses, and that two mesothelioma patients had symptomatic 
improvement (110). 
High levels of interleukin-4 (IL-4) receptor expression have been shown on fresh human 
mesothelioma specimens and correlated with a worse outcome. In a human mesothelioma 
xenograph, nude mouse model, intratumoral injection of the recombinant toxin IL-4 (38–37)-
PE38KDEL significantly reduced tumor volumes in a dose-dependent manner compared to 
the control and IL-4-treated mice (111).  
 
 
Immune checkpoint inhibitors 
Cytotoxic T lymphocyte antigen-4 (CTLA-4) is vital for maintaining host immune tolerance 
to established tumors. A Phase II trial evaluating anti-CTLA-4 antibody (tremelimumab) in 
29 patients with chemotherapy-resistant advanced mesothelioma (28 pleural and 1 peritoneal) 
has been recently reported (112).  Objective clinical responses have been observed in only 2 
of 29 patients (6,9%) and disease stabilization has been noted in 9 patients (31%).  
Programmed death receptor is found on the surface of T-cells and its stimulation leads to T-
cell deactivation, thus allowing escape from the immune system surveillance in the presence 
of otherwise antigenic substrate. Activation of this receptor occurs by a programmed death 
ligand 1 (PD-L1), which is present in the tumor microenvironment and on the surface of 
tumor cells. The effect of PD-L1 blockade on different subpopulations of T-cells has pro-
duced opposing effects on tumor progression, suggesting that tumor-derived immune 
suppression is mediated by specific subsets of T-cells (113). Several trials are currently 
evaluating the inhibition of this pathway using different agents (lambrolizumab and 




Multiple genetic abnormalities have been identified in MPM, and a variety of genetic 
manipulation strategies have been employed in preclinical studies. 
	   30 
Suicide gene therapy utilizes engineered viruses that deliver transgenes encoding enzymes 
that metabolize pro-drugs into toxic metabolites capable of killing tumor cells. In a clinical 
trial conducted with intrapleural Adenovirus herpes simplex thymidine kinase/ganciclovir, a 
few patients have experienced prolonged survival, suggesting the induction of antitumor 
immunity in addition to acute viral-mediated cytotoxicity (114). 
Another gene therapy strategy involves the administration of viral vectors encoding specific 
cytokine genes that may exert a direct cytotoxic effect on tumor cells or alter immunologic 
responses to the tumor. For instance, several clinical trials have evaluated adenoviral-




Immunotherapy and vaccines 
The rationale for immunotherapy in mesothelioma stems from the observation that patients 
whose tumor demonstrated lymphocytic infiltrate had a better prognosis. This kind of therapy 
has focused on both passive immunity, where effectors such as cytokines are used to activate 
the host immune system, and active immunity, where the lymphocytes of a patient are 
exposed to cancer-specific antigens (116). Several ongoing studies using immunotherapy in 
MPM have shown some early promise. Preclinical in vitro and in vivo data support the use of 
dendritic cell vaccines as a valuable strategy in mesothelioma (117).  
 
 
Direct physical cytotoxic therapies 
Photodynamic therapy (PDT) is a type of cancer treatment based on the premise that 
unicellular organisms, if first treated with certain photosensitive drugs, will die when exposed 
to light at a particular frequency. PDT destroys cancerous cells by using this fixed frequency 
light to activate photosensitizing drugs which have accumulated in body tissues. In a Phase I–
II experience, the median disease-free progression has been set to 15 months, obtaining an 
overall survival of over 40 months (118).  
Experimental data suggest that heating chemotherapeutic agents increases their entry into 
tumor cells. Data come from Phase I–II studies have evaluated the systemic toxicity of 
intrapleural drug (most commonly cisplatin) administration in highly selected patients. 
However, evidence supporting the use of hyperthermia is quite limited (119). A Phase I–II 
trial of intraoperative hyperthermic (41°C) iodine–povidone lavage following surgery (either 
P/D or EPP) has been recently reported (120). Although this treatment has been well tolerated 
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and the surgical outcomes have been acceptable, convincing evidence of its efficacy is still 
lacking. 
Cryotherapy has been used for decades in the treatment of cancer (121). This kind of 
treatment may improve the immune response through enhanced natural killer cell activity, T-
cell responses and systemic IFN production. A recent study reports the use of percutaneous 
cryoablation in 24 mesothelioma patients for control of limited recurrent local disease 
following P/D. The treatment was well tolerated, and was associated with a median survival 
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CANCER CHEMOPREVENTION USING NATURAL PRODUCTS  
Pharmacological activities associated with natural products have been recognized since the 
beginning of mankind. Despite the vast interest in diet as a mode to prevent and cure cancer, 
it was not until the late 20th century that the mechanism of action of diet-derived 
chemoprevention began to unravel. The beneficial effects of fruits and vegetables have been 
attributed, among others, to the high content of bioactive compounds that are non-nutrient 
constituents commonly present in food (123).  
Natural products are important sources of anti-cancer lead molecules. Many successful anti-
cancer drugs are natural products or their analogues. Natural products have been used for the 
treatment of various cancers and are becoming an important research area for drug discovery. 
These products, especially phytochemicals, have been extensively studied and have exhibited 
anti-carcinogenic activities by interfering with the initiation, development and progression of 
cancer through the modulation of various mechanisms, including cell proliferation, 
differentiation, apoptosis, angiogenesis, and metastasis (Fig. 7).  This concept is gaining 
attention because it is a cost-effective alternative to cancer treatment.  
Drug toxicity continues to be a subject of great concern. Chemoprevention, by definition, is a 
means of cancer control by which the occurrence of the disease can be entirely prevented, 
slowed down, or reversed by the administration of one or more naturally occurring and/or 
synthetic agents. Chemoprevention began in the 1920s with Isaac Berenblum (124) and, after 
a period of relative dormancy, re-entered the cancer research mainstream in the 1970s through 
the work of Michael D. Sporn (125). 
In recent years, natural dietary agents have drawn a great deal of attention from both 
researchers and the general public, because of their potential ability to suppress ongoing 
cancer and reduce the risk of cancer development. A major group of these products is 
represented by antioxidants, while other compounds include reactive chemicals endowed with 
cytoprotective properties. These natural products are found in vegetables, fruits, plant 
extracts, and herbs. Most of non-nutrient antioxidants in food are phenolic or polyphenolic 
compounds, such as isoflavones in soybeans, catechins in tea, phenolic esters in coffee, 
phenolic acids in red wine, quercetin in onions, and rosmarinic acid in rosemary (126). 
Multiple epidemiological and animal studies have made it clear that the consumption of food 












Figure 7. Molecular targets of natural chemopreventive agents. The cell signaling pathways activated by natural dietary 
agents are numerous and different for different agents. Multiple growth factor receptors (epidermal growth factor receptor, 
insulin-like growth factor 1 receptor, fibroblast growth factor, platelet-derived growth factor receptor) are activated at the cell 
surface in tumorigenesis. Activation of these receptors activates several downstream signaling pathways. Among these 
pathways, the Ras-MAPK (such as ERK and JNK) pathways, the JAK-STAT pathways, the PI3K-AKT pathways and the 
NF-κB pathways are important and are the targets of natural chemopreventive agents. Some natural agents inhibit the 
receptors at the cell surface either by dephosphorylating them or by inducing their degradation, which ultimately modulate 
the downstream signaling pathways important for proliferation, angiogenesis, and apoptosis. Inhibition of AKT and ERK 
signaling by natural agents is quite common, although in many cases this inhibition is the result of growth factor receptor 
inhibition. Inhibition of NF-κB signaling pathway by interfering with multiple targets of signaling is another common target 
of natural agents. Many natural compounds generate reactive oxygen species (ROS), which activate p53 family members and 





and Nrl), and ATF (ATF2, LRF1/ATF3, B-ATF, JDP1, JDP2) subfam-
ilies.159 These proteins form either homo- or heterodimers and bind
either to AP-1 DNA recognition elements (5‘-TGAG/CTCA-3‘) or to
cAMP response elements (5‘-TGACGTCA-3‘) and activate their tar-
get genes. In addition to being transcriptional activators, an increasing
body of evidence suggests that some of the biologic effects of AP-1 are
mediated by gene repression.159 AP-1–regulated genes include impor-
tant modulators of invasion and metastasis, angiogenesis, prolifera-
tion, differentiation, and survival.159
Several natural chemopreventive compounds such as green
tea,160 resveratrol,161 and curcumin162 have been reported to suppress
AP-1 activation and modulate AP-1 target genes, which is ultimately
link d to their chemopreventive potential. r en tea polyp e ols
inhibit the transcriptional activity of AP-1 in multiple cells types,
which is essential for their growth inhibitory effects.160,163 Pretreat-
ment with resveratrol inhibits TPA-induced AP-1 DNA binding by
inhibiting the nuclear expression of c-Jun and c-Fos.161 Multiple stud-
ies also suggest that suppression of AP-1 activity is important for
mediating the proapoptotic function of curcumin. Curcumin reduced
cell survival of human glioma cells, which was correlated with the
inhibition of AP-1 and NF-!B signaling pathways.162
Signal Transducers and Activators of
Transcription Pathway
A novel signal transduction pathway to the nucleus has been
uncovered through the study of transcriptional activation in response
to interferon.164 Activation of various tyrosine kinases leads to phos-
phorylation, dimerization, and nuclear localization of the signal trans-
ducers and activat rs of tra scription (STAT) pr teins, binding to
specific DNA elements and direct transcription. So far, seven mam-
malian STAT family members (STAT1, STAT2, STAT3, STAT4,
STAT5A, STAT5B, and STAT6) have been clo ed that share common
structural elements. Constitutive activation of STAT3 and STAT5 has
been implicated in multiple myelomas, lymphomas, leukemias, and
several solid tumors.165 Several dietary agents, such as green tea,166
resveratrol,167 and curcumin,168 have been implicated to modulate
STAT activation in tumor cells. Consumption of GTP substantially





























































Fig 2. Molecular targets of natural chemopreventive agents. The cell signaling pathways activated by natural dietary agents are numerous and different for different
agents. Multiple growth factor receptors (epidermal growth factor receptor, insulin-like growth factor 1 receptor, fibroblast growth factor, platelet-derived growth factor
receptor) are activated at the cell surface in tumorigenesis. Activation of these receptors activates several downstream signaling pathways. Among these pathways,
the Ras-MAPK (such as ERK and JNK) pathways, the JAK-STAT pathways, the PI3K-AKT pathways and the NF-!B pathways are important and are the targets of natural
chemopreventive agents. Some natural agents inhibit the receptors at the cell surface either by dephosphorylating them or by inducing their degradation, which
ultimately modulate the downstream signaling pathways important for proliferation, angiogenesis, and apoptosis. Inhibition of AKT and ERK signaling by natural agents
is quite common, although in many cases this inhibition is the result of growth factor receptor inhibition. Inhibition of NF-!B signaling pathway by interfering with
multiple targets of sign ling is another common target of natural agents. Many natural compounds generate reactive oxygen species (ROS), which activate p53 family
members and induce cell cycle arrest and apoptosis. EGCG, epigallocatechin-3-gallate; ERK, extracellular signal–regulated kinase.
Amin et al
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NATURAL PRODUCTS AS TREATMENT IN MPM 
Conventional therapies for MPM cause serious side effects and, at best, merely extend the 
patient’s lifespan by a few years. There is thus the need to utilize alternative concepts or 
approaches to the prevention and treatment of cancer. 
Natural products, especially those from terrestrial plants and microbes, have long been a 
traditional source of drug molecules. Modern pharmaceutical discovery programmes owe 
much to natural products. Indeed, pharmacologically active compounds from plants and 
microbes represent an important pipeline for new investigational drugs. 
Previous research has revealed that some natural compounds act on MPM cells. 
Specifically, ascorbate (AA) and the green tea polyphenol epigallocathechin-3-gallate 
(EGCG) are selectively cytotoxic to MPM cells with respect to normal mesothelial cells. AA 
promotes the formation of H2O2 in the cell medium, and its toxicity is suppressed by 
extracellular catalase. The data indicate that AA-induced extracellular H2O2 production 
induces a strong oxidative stress in MPM cells because of their high rate of superoxide 
production. This explains the selective toxicity of AA to MPM cells (128).  
EGCG exerts an MPM antitumor effect, as shown by its selective in vitro cytotoxicity on 
MPM cells through a mechanism of action based on extracellular H2O2 production, Ca2+ 
homeostasis loss, and intracellular ROS increase. EGCG induces H2O2 release at the outside 
of cells that acts by inducing T-channel opening at the plasma membrane. Ca2+ leakage into 
the cytosol causes [Ca2+]i rise and triggers ROS production. Ca2+ and ROS cooperate in 
inducing either apoptosis or necrosis, depending on damage (129).  
In an in vitro screening of various AA/drug combinations, AA and EGCG showed synergistic 
effects against MPM cells with the standard antitumor drug gemcitabine. A triple combined 
treatment based on EGCG, AA and gemcitabine (AND therapy for Active Nutrients/Drug) 
reduces mesothelioma growth and metastatization, suggesting its possible use in the clinical 
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Aims 
Polyphenols are an important group of phytochemicals that has gained increased research 
attention since it was found that they could affect cancer cell growth. Initial evidence came 
from epidemiologic studies suggesting that a diet that includes regular consumption of fruits 
and vegetables (rich in polyphenols) significantly reduces the risk of cancer. (131). 
In the following works I have studied the effects of different types of polyphenols (oleuropein 
(OL), hydroxytyrosol (HT) and resveratrol (Res)) on malignant mesothelioma cancer cells. 
Oleuropein and its metabolite hydroxytyrosol are phenolic compound found in olive leaf and 
fruit. Hydroxytyrosol is a simple phenol and oleuropein is a secoiridoid (Fig. 8). 
 
 
                
	  
	  
Figure 8. Structures of oleuropein and hydroxythyrosl 
 
 
Hydrolysis of oleuropein, which occurs during olive oil storage, results in the formation of 
hydroxytyrosol (132). 
OL and HT represent the molecules of major interest for their biological and pharmacological 
properties, and, with no doubt, are among the most investigated antioxidant natural 
compounds (133). OL has several pharmacological properties, including antioxidant (134), 
anti-inflammatory (135), anti-atherogenic (136), anti-cancer (137), antimicrobial (138), and 
antiviral effects (139). In addition, it has been shown to exhibit anti-ischemic and 
hypolipidemic activities (140). For these reasons, oleuropein is commercially available as 
food supplement in Mediterranean countries. 
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Resveratrol (trans-3,5,4’-trihydroxystilbene) is a phytoalexin found in many plant species, 
including various human food such as grapes, peanuts, and berries; it is produced in plants in 






Figure 9. Structure of resveratrol 
 
 
Resveratrol has attracted increasing attention since 1992, when it was associated with the 
cardioprotective effects of red wine consumption, a phenomenon commonly known as the 
“French Paradox” (141). Thereafter, a wide range of favorable properties has been attributed 
to resveratrol in many illnesses, including cardiovascular diseases (142), ischemic injuries 
(143), diabetes (144), inflammation (145), neurodegenerative diseases (146), and cancer (147, 
148). 
Resveratrol can affect the processes underlying all three stages of carcinogenesis, viz. tumor 
initiation, promotion, and progression. It has been found to exert strong anti-proliferative 
properties on many cultured cancer cell lines, being able to arrest cell cycle and induce 
apoptosis, and suppress angiogenesis and metastatization (149 - 151).  
Resveratrol is a potent regulator of genomic and non-genomic processes, including the 
regulation of membrane potential, DNA transcription, enzyme activity, secretion, apoptosis, 
mitochondrial activity, and intracellular ion homeostasis, including the regulation of cytosolic 
Ca2+ (152). 
Polyphenol anticancer effects have been attributed not only to their ability of acting as 
antioxidants but also to their ability to interact with basic cellular mechanisms. Such 
interactions include interference with membrane and intracellular receptors, interaction with 
the basic enzymes involved in tumor promotion and metastasis, interaction with oncogenes 
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and oncoproteins, and, finally, modulation of intracellular calcium (Ca2+) signaling and 
homeostasis. (153).  
Intracellular calcium (Ca2+) is an essential signal transduction element involved in several 
physiological functions, such as cell growth and proliferation, cell cycle control and gene 
expressions (154). Although changes in Ca2+ homeostasis may not be a necessity for 
malignant initiation, modified Ca2+ signaling in cancer cells is thought to contribute to 
important events during tumor progression, including proliferation, migration, invasion, and 
metastasis (155). 
This study has been devoted to explore the effects of the above polyphenols, i.e. resveratrol, 
hydroxytyrosol and oleuropein, on MPM cells in terms of Ca2+ mobilization. Mechanisms of 
action have also been pursued for these effects, in order to individuate possible therapeutic 
targets to be addressed for a Ca2+-mediated, antiproliferative use of these polyphenols, 
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Malignant mesothelioma is a poor prognosis cancer in urgent need of alternative therapies. Oleuropein, the major phenolic of
olive tree (Olea europaea L.), is believed to have therapeutic potentials for various diseases, including tumors. We obtained an
oleuropein-enriched fraction, consisting of ($%w/w oleuropein, from olive leaves, and assessed its e)ects on intracellular Ca2+ and
cell viability in mesothelioma cells. E)ects of the oleuropein-enriched fraction on Ca2+ dynamics and cell viability were studied in
the RENmesothelioma cell line, using fura-#microspectro*uorimetry andMTT assay, respectively. Fura-#-loaded cells, transiently
exposed to the oleuropein-enriched fraction, showed dose-dependent transient elevations of cytosolic Ca2+ concentration ([Ca2+]i).
Application of standard oleuropein and hydroxytyrosol, and of the inhibitor of low-voltage T-type Ca2+ channels NNC-%%-$&+(,
suggested that the e)ect is mainly due to oleuropein acting through its hydroxytyrosol moiety on T-type Ca2+ channels. 'e
oleuropein-enriched fraction and standard oleuropein displayed a signi,cant antiproliferative e)ect, as measured on REN cells
by MTT cell viability assay, with IC50 of ## !g/mL oleuropein. Data suggest that our oleuropein-enriched fraction from olive leaf
extract could have pharmacological application in malignant mesothelioma anticancer therapy, possibly by targeting T-type Ca2+
channels and thereby dysregulating intracellular Ca2+ dynamics.
1. Introduction
Malignant mesothelioma is a poor prognosis cancer with
worldwide increasing insurgence, arising from the pleura and
other mesothelial tissue and showing close association with
asbestos exposure. An e)ective therapeutic approach for the
disease is currently lacking, while alternative treatments are
urgently needed [!]. Among alternative remedies for cancer
treatment, there is a growing interest in the anticancer action
of natural substances, some of which are present in large
amounts in byproducts from agrofood chains.
Olive (Olea europaea L.) is a main temperate fruit crop,
mostly destined to oil production [#].Olive oil is reputed to be
an important health promoting factor in the Mediterranean
diet, especially because of its alleged prevention of cardio-
vascular problems, metabolic syndrome, cancer, alleviation
of in*ammatory and autoimmune conditions, and wound
healing [&]. However, olive tree leaves have a several-century-
long tradition in the folk medicines of the Mediterranean
basin and are currently contemplated in the Pharmacopoeia
Ph. Eur. % ["].
Leaves and other materials from olive tree pruning
accumulate in yearly amounts as high as about #% kg per tree
[%].'is material is generally disposed by olive tree growers,
representing an overhead cost of olive and oil production,
while the possibility of using it as biomass for thermal energy
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is under study ["]. Olive leaves are used in the form of herbal
extracts, tea, and powder for nutritional supplement and
cosmetics [#], but these products represent aminimal portion
with respect to the huge amount of disposed materials.
$e major leaf secondary metabolite is the secoiridoid
oleuropein, a glycosylated ester of elenolic acid with hydrox-
ytyrosol (!-(%,#-dihydroxyphenyl)ethanol). Oleuropein leaf
content has been reported to vary about tenfold among di&er-
ent olive varieties, rating on average between '( and '((mg/g
of dry matter [), *]. Many other biologically active phenolics
are present in olive leaves, including hydroxytyrosol itself [+].
Oleuropein is deemed to have great potential as an antiox-
idant and food additive, but also as a possible therapeutic
tool. A wide range of studies on oleuropein have been carried
out using in vitro assays, animal models of disease, or human
volunteers, in order to explore possible bene,cial e&ects for
human health ['(]. $e reported ,ndings mainly include
antioxidant and anti-in-ammatory e&ects, hepatoprotection,
neuroprotection, hypoglycemic and hypolipidemic activities,
and cardiovascular protection ['', '!]. Antiproliferative activ-
ities on cancer cell lines, antitumor e&ects in animals, and
antimicrobial and antiviral e&ects have also been shown ['%].
Hydroxytyrosol in olive leaves, fruits, and extracts is
believed to derive from oleuropein hydrolysis, both by spe-
ci,c enzymes and as an extraction artifact [+]. In vitro and
in vivo studies suggest that this compound shares remarkable
antioxidant and anti-in-ammatory power with oleuropein,
allegedly related to antiatherogenic, antithrombotic, cardio-
protective, and anticancer e&ects ['#, '.].
$e value of olive leaf extract for possible use in health
products and medical food has been previously assessed in
terms of antioxidant and antimicrobial power ['"]. However,
the pro,table reutilization of agrofood chain byproducts
needs to overcome several problems, including the costs
of transport and processing and the seasonal availability of
these materials. In this study, we have developed a rapid
method for obtaining olive leaf extract enriched in oleu-
ropein, involving raw extraction, extract partitioning, and
chromatographic separation.$e material has been tested in
pharmacologically relevant, intracellular Ca2+ mobilization
assay and antiproliferative assay on mesothelioma cells. In
these experiments, standard oleuropein has been used as
control, while hydroxytyrosol has been also used in Ca2+
assays to provide insight into the Ca2+ mobilizing properties
of the oleuropein molecule.
2. Materials and Methods
!.". Plant Material. Branch specimens of Olea europaea L.
cultivar “Taggiasca” [')] were obtained from olive groves
located at Imperia, Italy, owned by the Pietro Isnardi S.r.l.
food company. $e material was taxonomically identi,ed
by one of us (LC), and a voucher specimen was deposited
at DISTAV, University of Genova (cat.: GE-Olea europaea
cultivar “Taggiasca”). Leaves were separated from twigs, air-
dried for one week, minced to <'mm using a grinder, and
then subjected to extraction procedure.
!.!. Reagents and Solutions. HPLC grade methanol Chro-
masolv (>++.+%) and glacial acetic acid were purchased
from Sigma-Aldrich (Milwaukee, USA). Ammonium acetate
(++%) was acquired from Fluka (Buchs, Switzerland). Ultra-
pure water was produced by a Millipore Milli-Q system
(Milford, USA). Analytical grade chemicals were purchased
from Sigma-Aldrich, unless otherwise speci,ed.
For LC/MS analysis, standard stock solutions of oleuro-
pein and hydroxytyrosol (each at concentration of
'((.(mgL!1) were prepared in methanol and diluted as
required with a bu&er solution of ammonium acetate
'(.(mM brought to pH #.( for acetic acid. For in vitro
bioassays, stock solutions of oleuropein and hydroxytyrosol
(each at '((mM) were prepared in DMSO and diluted
as indicated with cell medium or loading bu&er for Ca2+
measurements. Stock solutions were preserved at !!("C in
dark conditions and were stable for three months.
!.#. Olive Leaf Extraction Procedure. $e minced leaves
were extracted with a mixture of !-propanol : water of + : '.
Aliquots of '( g of leaves were extracted twice with !((mL
of solvent each time. $e extraction was carried out at RT
for about '.. h. $e resulting solutions were mixed and the
solvent was eliminated under vacuum, yielding an amount of
!.%. g of driedmaterial.$is raw extract was then partitioned
between a mixture of methanol : water of % : ' and a mixture
of toluene : petroleum ether of ! : ' ('((mL each phase). $e
hydrocarbon phase became deep green, indicating that it
contained all the chlorophyll of the raw extract.$e aqueous
methanol phase was dried under vacuum, yielding '.* g of
subextract.$is material was then again partitioned between
water and !-butanone ('((mL each phase), to remove sugars
and other water-soluble compounds. $e organic phase was
dried out, obtaining a partitioned subextract that amounted
to '.(% g (#%% recovery from the ,rst raw extract, '(% from
the plant material). A control TLC showed that in the former
partition no oleuropein passed in the hydrocarbon phase,
while in the latter only a tiny amount of it was lost in thewater
phase.
!.$. Chromatographic Separation. Liquid chromatography
was performed by means of an MPLC system, consisting of
an Alltech #!" HPLC pump equipped with a VWR LaPrep
%'(' detector. Glass columns from Omni,t were used, home-
packed with Fluka silica gel '((RP-'* ('.–%. "m) stationary
phase. TLC was performed with Merck F254 glass plates (RP-
'*); the spots were detected using a UV lamp (!.# and
%"" nm) and additionally by spraying with sulfovanillin and
heating at '(("C, obtaining an oleuropein coral pink spot on
TLC.
$e above subextract was loaded on a RP-'* preparative
column and eluted with *(% water and !(%methanol. Frac-
tioningwasmonitored through theUVdetector (#= !.(nm)
and with TLC. Finally, an oleuropein-enriched fraction was
collected and subjected to further study.
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!.". LC/MS Analysis
!.".#. Apparatus. LC/MS analysis was performed on the
above raw extract and subfractions by Nexera Liquid Chro-
matography Shimadzu (Kyoto, Japan) system equipped with
a DGU-"#A!R Degasser, two LC-!#AD Pumps, a SIL-!#AC
Autosampler, a CTO-"#AC column compartment, and a
CMB-"#A Lite system controller. $e system was interfaced
with a !"## QTrap LC-MS/MS system (AB Sciex, Concord,
Canada) by a Turbo V interface equipped with an ESI probe.
$e !"##QTrap data were processed byAnalyst %.&." so'ware
(Toronto, Canada).
!.".!. UHPLC-MS/MS Conditions. $e stationary phase was
a Kinetex C%( column (".%mm ! %##mm, ".)"m) (Phe-
nomenex, Italy). $e mobile phase was a mixture of ammo-
nium acetate %#.#mM in ultrapure water with the addition
of #.%% acetic acid (A), and aqueous ammonium acetate
%#.#mM/methanol &/*& (v/v) with the addition of #.%% acetic
acid (B), eluting at +ow-rate #.,##mLmin!1 in the following
gradient conditions: #.#–#.&min &% B, #.)–(.#min )&% B,
(.%–%".#min %##% B, and %".%–%&.#min &% B. $e injection
volume was &.#"L. Oven temperature was set at ,#"C.
$e turbo ion spray (TIS) ionization was obtained using
the Turbo V interface working in negative ion mode. $e
instrumental parameters were set as follows: curtain gas (N2)
at !# psig, nebulizer gas GS% and GS" at &# and ,# psig,
respectively, desolvation temperature (TEM) at &&#"C, col-
lision activated dissociation gas (CAD) at ) units of the
arbitrary scale of the instrument, and ion spray voltage (IS)
at #,&##V.
$e !"## QTrap was used in scheduled multiple reaction
monitoring (sMRM) considering the transitions of each
species at a pre-xed retention time. Unit mass resolution
was established and maintained in each mass-resolving
quadrupole by keeping a full width at half maximum
(FWHM) of about #.. u.
$e analytes were previously subjected toMS/MS charac-
terization study, to identify the fragmentation patterns taking
place under increasing collisional energy. Characterization
experiments were carried out for direct infusion of %.#mgL!1
standard solutions of each analyte connected through a T
valve to the syringe pump (syringe +ow-rate "#.#"Lmin!1;
chromatographic pump +ow-rate "## "Lmin!1). For each
species, the most intense transition was used for the quan-
titative analysis and referred to as “quanti-er” transition,
while the second intense one (the “quali-er” transition) was
employed in the identi-cation step, as a con-rmation. $e
“quanti-er” and “quali-er” transitions and the instrumental
potential values for each compound are reported in Table %.
Calibration plots of -ve concentration levels (between
LOQ value and %###.#"g L!1), relating the peak area of the
“quanti-er” transition signal ($) versus standard concentra-
tion (%), were built for all the analytes. To avoid a possible
in+uence of the experimental error on the execution order of
analyses, the standard solutions were injected in randomized
order. For all the analytes a linear regression -t was used with
a weighting factor 1/% and for all the calibration plots a good
linearity with regression coe/cients (&2) always greater than
#.**(" was obtained.
Detection limit values expressed as the concentration of
the analyte that gives a signal equal to the average background
('blank) plus ! times the standard deviation of the blank
(LOD = 'blank + 3(blank) are #.!"g L!1 for hydroxytyrosol
and #.,"g L!1 for oleuropein.$e quantitation limits (LOQ),
evaluated as LOQ= 'blank + 10(blank, are %.# "g L!1 for hydrox-
ytyrosol and %." "g L!1 for oleuropein.
!.$. In Vitro Cell Culture. In vitro experiments were carried
out using the tumorigenic malignant mesothelioma REN cell
line [%]. Cells were grown in DMEM, supplemented with %#%
foetal bovine serum (FBS, Euroclone), at !."C, in a &% CO2,
fully humidi-ed atmosphere.
!.%. Cell Viability Assay. Cell viability was determined on
REN cells by the MTT assay. Cells were settled in *)-well
plates for ", h, exposed to various agents for ,( h as speci-ed,
incubated with %##"L/mL tetrazolium salt (MTT, &mg/mL
in PBS) in cell culture mediumwithout serum for ! h at !."C,
and treated with a solution of %N HCl-isopropanol (% : ",,
v/v) followed by mixing to dissolve the dark-blue formazan
crystals formed. A'er a few minutes at room temperature,
the plates were read at &&# nm in a VMax microplate reader
(Molecular Devices, Sunnyvale, CA).
!.&. Intracellular Ca!+ Measurements. Cytosolic free Ca2+
concentration was measured in fura-"-loaded REN cells
using a microspectrophotometry +uorescence-ratio setup
equipped with a perfusion system, as previously described
[%(]. Cells were incubated in loading bu0er containing %# "M
fura-"-AM at !."C for !# minutes, washed with bu0er, and
mounted on the stage of an inverted microscope (Axiovert
Zeiss, Germany), where they were continually superfused
with di0erent solutions. Cells were illuminated by a xenon
lamp through a wavelength selector monochromator; emis-
sionwas observed through!,# quartz objective and recorded
by a photomultiplier.$e ratio)340/)380 was calculated every
,#msec to acquire a time-dependent internal Ca2+ sensitive
signal.
At the end of each experiment, cells were incubated with
%# "M ionomycin in a Ca-free solution containing "mM
EGTA for "##,#min until the ratio reached a minimum
value (&min); then EGTA was washed out, normal external
Ca2+ (%mM) was restored, and the ratio readily reached a
maximum value (&max). Finally, MnCl2 (&mM) was added to
the bath to quench the fura-" +uorescence and determine the
background (cell auto+uorescence) values. $e +uorescence
emissions relative to each excitation wavelength ()340 and)380, resp.) were corrected for this background signal before
ratio & = )340/)380 determination. Internal Ca2+ was cal-
culated according to the Grynkiewicz equation [%*].
!.'. Statistics. Statistics were obtained with the & package,
version !.#.% (http://www.r-project.org/foundation/), using *-
test with Bonferroni’s correction for multiple comparisons.
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T"#$% &: sMRM NI transitions (Q& and Q' masses) and mass spectrometry parameters. (e two most sensitive transitions for each species
were monitored.
Analytes Q& (!/") Q' (!/") #! (min) DP (V) EP (V) CEP (V) CE (V) CXP (V)
Hydroxytyrosol &)' &*'/+' '.! $'! $,) $&,.'* $*-/$'& $&.-./$&.')
Oleuropein )'+ *,)/'-, ,.+ $!- $) $'&./& $*./$*+ $&..+/$*.&*"!: retention time; DP: Declustering Potential; EP: Entrance Potential; CEP: Collision cell Entrance Potential; CE: Collision Energy; CXP: Collision cell eXit
Potential.
T"#$% *: Percent content (w/w) of oleuropein and hydroxytyrosol in
di0erent olive leaf extracts.
RE SE EF
Oleuropein *&.! ± -.' !'.* ± &.! /-.& ± -.'
Hydroxytyrosol -.', ± -.-! -.+& ± -.-' n.d.
Data are means ± s.d. of three independent measures. RE: raw extract; SE:
subextract; EF: oleuropein-enriched fraction; n.d.: not detected.
Cytotoxicity was determined using a logistic dose-response
curve as reported in Ranzato et al. [*-]. Analysis of data from
Ca2+ measurements and determination of EC50 values were
done by Sigmaplot . (Systat So1ware Inc., San Jose, CA).
3. Results
Multistep processing of olive leaves consisted of the following:
(&) extraction of dried, minced leaves in *-propanol : water
(+ : &), to obtain a raw extract; (*) partitioning between
methanol : water (' : &) and toluene : petroleum ether (* : &),
followed by partitioning of the dried aqueousmethanol phase
between water and *-butanone, to obtain a subextract; (')
liquid (column) chromatography separation of the dried
organic phase, to obtain an oleuropein-enriched fraction (see
Methods). Oleuropein and hydroxytyrosol quanti2cation in
the raw extract and fractions was achieved by LC-MS tech-
nique. Data showed a progressive enrichment in oleuropein,
up to a value of /-% w/w in the 2nal fraction obtained
through chromatographic separation (Table *).
In order to evaluate the pharmacological potentials of the
oleuropein-enriched, leaf extract fraction, and of its major
component oleuropein, we tested the ability of mobilizing
cell Ca2+ in mesothelioma REN cells. Intracellular Ca2+ is a
main regulator of cell growth, and therefore agents able to
deregulate Ca2+ dynamics can be possibly used to hinder cell
proliferation.
Fura-*-loaded cells were transiently exposed by perfusion
to the oleuropein fraction. (is treatment induced [Ca2+]i
rises followed by a prompt recovery of the baseline level upon
washout (Figure &(a)). Data indicate that the observed [Ca2+]i
spikes are not due to cell membrane injury but rather depend
on the in3ux of Ca2+ through membrane Ca2+ channels.
Moreover, the [Ca2+]i transient elevations were dependent
on the nominal concentration of oleuropein (&-–'- %M)
contained in the extract (Figure &(b)).
To explore more in depth the mechanism of action, we
also studied the Ca2+ mobilizing property of standard oleu-
ropein. Similar to the oleuropein fraction, increasing doses of
standard oleuropein, in the range &-–&-- %M, induced dose-
dependent [Ca2+]i spikes (Figures &(c) and &(d)). Removal
of Ca2+ from the external solution almost abolished the
oleuropein e0ect (Figure &(d)). In addition, the use of the
T-type Ca2+ channel inhibitor NNC-))--'+/ (Sigma, &+.%,
HPLC) [*&] reversibly reduced the Ca2+ spike induced by
the highest dose of &-- %M oleuropein (Figures &(c) and
&(d)), suggesting at least a partial involvement of T-type Ca2+
channels.
We tried to provide some hint as to which oleuropein
moiety could be active on cell Ca2+ mobilization. Hydrox-
ytyrosol is known to induce modulatory e0ects on [Ca2+]i
[**]. We therefore used standard hydroxytyrosol on fura-*-
loadedREN cells, observing the induction of dose-dependent[Ca2+]i spikes that also in this case were inhibited by Ca2+-
free medium. Moreover, NNC-))--'+/ also hindered the
hydroxytyrosol-induced [Ca2+]i spikes, with .-% inhibition
at &- %M hydroxytyrosol and /)% inhibition at &--%M
hydroxytyrosol (Figures &(e) and &(f)).
As for comparative quanti2cation of the e0ect on [Ca2+]i,
dose-response data allowed estimating an EC50 of &* %M
for hydroxytyrosol and of )'%M for oleuropein, showing
that hydroxytyrosol is more powerful than oleuropein in
inducing Ca2+ spikes. No established drug is known to
induce T-type Ca2+ channel opening. We therefore used
the natural phenolic epigallocatechin-'-gallate (EGCG) as
positive control, since we had previously shown that this
compound induces Ca2+ rise in REN cells via T-type Ca2+
channels [*']. Presently, EGCG was found to induce dose-
dependent [Ca2+]i spikes with an estimated EC50 of /+ %M
(Figures &(e) and &(f)).
(e oleuropein-enriched fraction and standard oleu-
ropein were separately used on REN cells at nominally
equivalent oleuropein concentrations, in order to verify their
antiproliferative activity. EGCG was used as positive control
also in this case, since we had previously assessed its cytotox-
icity on REN cells [*!].(e cytotoxic e0ect of the oleuropein
fraction (IC50 = **%g/mL expressed as oleuropein) was
slightly, but not signi2cantly, stronger than that of standard
oleuropein (IC50 = *)%g/mL). Both substances were slightly
more cytotoxic than EGCG (IC50 = '' %g/mL) (Figure *).
4. Discussion
(e oleuropein yield in our enriched fraction is very close to
the highest concentrations present in commercially available
olive leaf extract formulations [*)], suggesting its possible
direct use in medicinal preparations. Despite a vast array of
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F"#$%& ': Time course of [Ca2+]i level in mesothelioma REN cells loaded with fura-( and alternatively exposed to the oleuropein-enriched
fraction from olive leaf extract (a, b), to standard oleuropein (c, d) or to standard hydroxytyrosol (e, f).)e oleuropein fraction and standard
oleuropein have been used at nominal concentrations of oleuropein, expressed in!moles/L. (a) Induction of [Ca2+]i spikes in RENcells loaded
with fura-( by transient exposure to the oleuropein fraction (ole) at '* and +* !Moleuropein. (b) Quanti,cation of dose-dependent induction
of [Ca2+]i spikes by the oleuropein fraction. Data are means ± s.e.m. (" # 3) of $[Ca2+]i (di-erence between peak value and basal level of[Ca2+]i). (c) Induction of [Ca2+]i spikes in REN cells by transient exposure to standard oleuropein (ole) at '* and '** !M. )e inhibitory
e-ect of the T-type Ca2+ channel blocker NNC-..-*+/! (. !M) and recovery a0er washout are shown. (d) Quanti,cation of dose-dependent
induction of [Ca2+]i spikes by standard oleuropein (EC50 = .+ !M), and inhibition by Ca2+-free medium (* Ca) or NNC-..-*+/!measured
at '** !M oleuropein. Data as above; % = & ' 0.01, ( test. (e) Induction of [Ca2+]i spikes by standard hydroxytyrosol (HT) at '* and '**!M,
inhibitory e-ect of NNC-..-*+/!, and recovery a0er washout. (f) Quanti,cation of dose-dependent e-ect of hydroxytyrosol (EC50 = '( !M)
and inhibition by Ca2+-free medium (* Ca) or NNC-..-*+/!measured at '* and '**!M hydroxytyrosol. Data and statistics as above. (g, h)
Induction of [Ca2+]i spikes by EGCG and statistics of dose-dependent e-ect (EC50 = !/ !M). Data as above.
data on possible oleuropein cellular targets, our data about
the e-ects on intracellular Ca2+ are new. )e activity of
oleuropein was slightly lower than that of the oleuropein-
enriched fraction, possibly due to the occurrence in the
fraction of other secoiridoid esters known to be present in
olive leaves, such as demethyloleuropein, ligstroside, and
oleuroside [(!], allegedly coeluting with oleuropein in the
HPLC separation.
We have previously found that low-voltage-activated T-
type Ca2+ channels, speci,cally the isoform Cav+.(, medi-
ate the Ca2+ rise induced in REN cells by the green tea
polyphenol epigallocatechin-+-gallate [(+]. We have also
shown that Cav+.( is responsible for Ca2+ spikes induced by
epigallocatechin-+-gallate in MCF-1 breast cancer cells [(*].
In the present study, an involvement of T-type Ca2+ channels
is called into question also for the Ca2+ mobilizing e-ect of
oleuropein by the use of Ca2+-freemedium, indicating a Ca2+
entry process, and of the speci,c T-type Ca2+ channel blocker
NNC-..-*+/!.
)e stronger activity of hydroxytyrosol with respect to
oleuropein and the inhibitory e-ect of NNC-..-*+/! suggest
that the hydroxytyrosol moiety could be the active site
mediating the oleuropein e-ect on T-type Ca2+ channels.
)e almost complete inhibition exerted by NNC-..-*+/!
on hydroxytyrosol at lower dose, compared with the partial
inhibition at higher dose, seems to indicate that the e-ect
of olive phenolics mostly involves a T-type Ca2+ channel-
dependent mechanism at low doses (''* !M). At higher
doses, these phenolics could instead act through amore com-
plex mechanism, possibly including other Ca2+ mobilizing
systems.
T-type Ca2+ channels have been linked to various kinds
of epilepsy [(1], while they are thought to play a role in
tumor cell cycle progression andproliferation [(2, (/].Hence,
much interest has been raised in their possible therapeutic
targeting with more or less speci,c inhibitors [+*, +'].
However, the blockage of these channels does not seem to be
an exclusive strategy in antitumor therapy. Antiproliferative
e-ects obtained with mibefradil and pimozide, two T-type
Ca2+ channel inhibitors, have been partially ascribed to
some unidenti,ed mechanism [+(]. Also, cell cycle progres-
sion needs a ,ne tuning of [Ca2+]i oscillations, suggesting
that intracellular Ca2+ dysregulation determining transient[Ca2+]i rise may also interfere with tumor development, pos-
sibly leading to cell death [++]. Accordingly, pharmacological
agents like olive phenolics, able to abnormally activate T-
type Ca2+ channel activity, could be promising tools for the
inhibition of cancerous cell growth.





























































IC50 = 33 (26–41)
(c)
F"#$%& ': Dose-response data of cell viability obtained with the MTT assay a(er exposure of REN cells for )* h to the oleuropein-enriched
fraction (+,% oleuropein) (a), standard oleuropein (b), and EGCG (c).-e charts show means ± s.d. of percent MTT-formazan absorbance,
logistic regression lines, and IC50 values expressed as !g/mL (./% CI). Concentrations are normalized as the logarithm of !g/mL.
In apparent contrast with the present data, it has been
previously shown that an olive leaf extract exerts antago-
nistic e0ects on high-voltage-activated L-type Ca2+ chan-
nel, thereby inducing blood pressure lowering [1), 1/]. A
comparison between these previous reports and our study is
di2cult tomake, owing to di0erences in both the extracts and
the experimental models. However, such a complex of data
advocates an intriguing scenario, entailing divergent e0ects of
major olive phenolics on low-voltage and high-voltage Ca2+
channels.
More insight into the possibility of using the oleuropein
fraction in antitumor treatment formesothelioma is provided
by our cytotoxicity tests, indicating that the antiproliferative
activity of the oleuropein fraction essentially depends on
its major constituent oleuropein. -e United States National
Cancer Institute plant screening program has established that
a plant extract can be deemed to have a cytotoxic e0ect if
IC50 for incubations of )*–!' h is ', !g/mL or lower [1+].
Our oleuropein-enriched fraction has an oleuropein content
of +,% and a cytotoxicity IC50 of '' (3!–'.)!g/mL in terms
of oleuropein. We can then estimate IC50 of 1+.! ('*.1–
)*.1) !g/mL for the oleuropein-enriched fraction as a whole.
Hence, our oleuropein fraction is close to the cytotoxicity
threshold established by NCI and could therefore be appro-
priate for the development of synergistic treatments allowing
reducing the doses of highly toxic conventional drugs, as
previously suggested for EGCG [3]. Such an approach could
overcome critical drawbacks in the treatment of chemoresis-
tant tumors like malignant mesothelioma [1!].
-ere is no established standard dose of oleuropein
for humans, but in acute toxicity studies, oleuropein and
hydroxytyrosol have shown no lethality or adverse e0ects
in mice up to doses of 3,,, and ',,,mg/kg, respec-
tively. In addition, studies conducted on humans with
olive extract or its polyphenolics have shown no undesired
e0ects [1*, 1.]. Pharmacokinetics of oral oleuropein and
its metabolite hydroxytyrosol in human plasma indicates
peaks of about ,.,,) !g/mL (,.,3!M) for oleuropein, while
its main metabolite hydroxytyrosol can reach values of
about ,.3/!g/mL (3 !M) [),]. -ese values are close to
the e0ective concentrations observed in our experiments
for hydroxytyrosol, but intravenous delivery of oleuropein
should allow reaching much higher blood peaks. Hence,
pharmacokinetics data indicate that plasma concentrations
compatible with dysregulating e0ects on tumor cell Ca2+
could be easily achieved upon clinical administrations of
	   58 
 
 
! Evidence-Based Complementary and Alternative Medicine
oleuropein, followed by its conversion into the more e"ective
metabolite hydroxytyrosol.
5. Conclusions
We have shown a method to obtain oleuropein-enriched
olive leaf extract fractions that could be of industrial interest,
because extraction is generally competitive with chemical
synthesis for complex molecules like oleuropein. In addi-
tion, we have highlighted a novel mechanism of action for
oleuropein and its metabolite hydroxytyrosol, consisting in
a dysregulation of Ca2+ dynamics occurring via T-type Ca2+
channels. #is kind of e"ect suggests a possible use of the
oleuropein fraction from olive leaves in the treatment of
mesothelioma.
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Abstract  
Aims: Intracellular calcium (Ca2+) is known to play an important role in cancer development 
and growth. Resveratrol (Res) is a stilbene polyphenol occurring in several plant species and 
known for various possible beneficial effects, including its ability to inhibit proliferation and 
to induce apoptosis in cancer cells. This study was designed to determine whether Res affects 
Ca2+ signaling in cancer cells. 
Main methods: We used the REN human mesothelioma cell line, as an in vitro cancer cell 
model, and the non-malignant human mesothelial MeT5A cell line, as normal cell model. 
Cytosolic Ca2+ concentration was measured by the fluorescent indicator Fura-2. 
Immunofluorescence, Western blot, and siRNA technique were employed to assess the 
involvement of T-type Ca2+ channels. Cell viability was determined by the calcein assay. 
Key findings: REN cells transiently exposed to 1–10 µM Res showed increasing peaks of 
Ca2+ that were absent in Ca2+-free medium and were reduced by non-selective (Ni2+), and 
highly selective (NNC 55-0396) T-type Ca2+ channels antagonist, and by siRNA knockout of 
Cav3.2 T-type Ca2+ channel gene. Dose-dependent curve of Res-induced Ca2+ peaks showed a 
rightward shift in normal MeT-5A mesothelial cells (EC50=4.9 µM) with respect to REN cells 
(EC50=2.7 µM). Moreover, incubation with 3 and 10 µM Res for 7 days resulted in cell 
growth inhibition for REN, but not for MeT-5A cells.  
Significance: Res induces Ca2+ influx, possibly mediated through T-type Ca2+ channels, with 
significant selectivity towards mesothelioma cells, suggesting a possible use as an adjuvant to 
chemotherapy drugs for mesothelioma clinical treatment.  
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1. Introduction   
Intracellular calcium (Ca2+) is an essential signal transduction element involved in several 
physiological functions, such as cell growth, cell cycle control, and gene expression (Berridge 
et al., 2003). In cancer cells, modified Ca2+ signaling is thought to contribute to important 
events, including proliferation, migration, invasion, and metastasis, while an alteration of Ca2+ 
regulatory mechanisms could be detrimental for tumor growth (Monteith et al., 2012). Plasma 
membrane Ca2+-permeable channels are a route of Ca2+ entry from the extracellular medium 
and sustain long-lasting intracellular Ca2+ elevations (Munaron et al., 2004). The possibility of 
arresting the proliferation of neoplastic cells by disturbing Ca2+ dynamics has led to a growing 
interest for Ca2+ channels as potential therapeutic targets (Monteith et al. 2007, Triggle 2007).  
Low-threshold voltage-dependent, or T-type Ca2+ channels (namely Cav3.1, Cav3.2, and 
Cav3.3, which consist of α1G, α1H and α1I subunits, respectively; (Zhang et al., 2013) are 
mainly present in excitable cells like nerve, muscle and endocrine cells, but are also 
abnormally expressed in various cancer cells, in which they are believed to promote cell 
proliferation via controlled increases of cytosolic Ca2+ (Taylor et al., 2008; Dziegielewska et 
al., 2014). These channels open at a membrane potential very close to, or even coincident 
with, the resting value (Perez-Reyes, 2003), thus they may drive a constant Ca2+ influx into 
the resting cell. Various studies indicate that antagonists of T-type Ca2+ channels may hinder 
the growth of certain cancer types (Li et al. 2011, Loughlin 2014).  However, the need for a 
fine adjustment of cytosolic Ca2+ variations in cell proliferation suggests that activators of 
Ca2+ channels might also act as antagonists of cancer growth (Monteith et al. 2007). 
Malignant pleural mesothelioma (MPM) is an aggressive, poor-prognosis tumor arising from 
the mesothelial lining cells of the pleura, commonly associated with asbestos exposure (Pass 
et al., 2004; Park et al., 2011). This cancer is in need of novel therapy, and among alternative 
remedies, there is a growing interest in the preventive action of active nutrients, like vitamins 
and polyphenols (Kampa et al., 2007) that may be used as tolerable drugs and exhibit 
synergistic effects with conventional chemotherapy (Volta et al. 2013). The inhibitory effect 
of polyphenols in tumorigenesis and tumor growth is apparently not due only to their 
antioxidant properties, but also to interferences with basic cellular functions such as 
apoptosis, cell cycle, angiogenesis, invasion, and metastasis (Kampa et al., 2007; Fantini et 
al., 2015). 
Previous studies conducted in our laboratory have revealed a synergistic behavior of the drug 
gemcitabine in combination with ascorbate and the green tea polyphenol epigallocatechin-3-
gallate (EGCG; Volta et al., 2013), while in another study we have reported intracellular Ca2+ 
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rise in mesothelioma cells treated with EGCG (Ranzato et al., 2012). Seeking other natural 
products that may be able to impair Ca2+ levels in mesothelioma cells, we used resveratrol 
(3,4′,5-trihydroxystilbene, Res), a stilbenoid produced by a wide variety of plants, such as 
grapes, peanuts, and mulberries, in response to stress, injury, ultraviolet irradiation, and 
fungal infection. This compound has shown a range of favorable properties in many illnesses, 
including cardiovascular diseases (Bradamante et al., 2004), ischemic injuries (Petrovski et 
al., 2011), diabetes (Su et al., 2006), inflammation (Martinez and Moreno, 2000), and 
neurodegenerative diseases (Anekonda, 2006). In particular, Res has been found to exert 
strong anti-proliferative properties on different cancer cell lines (Kundu and Surh, 2008; 
Frazzi and Tigano, 2014), being able to arrest cell cycle and induce apoptosis, as well as 
suppressing angiogenesis and metastasis (Trapp et al., 2010; Wang et al., 2010; Polycarpou et 
al., 2013). Being well tolerated by the human organism, and having multi-cellular targets, Res 
is an ideal candidate as a possible adjuvant of antitumor drugs. In this work we propose how it 
may explicate this role by dysregulating Ca2+ signaling. 
 
2. Materials and Methods 
2.1 Reagents 
Culture media and reagents were purchased from Sigma-Aldrich (St. Louis, MO, USA), 
unless otherwise indicated. 
2.2 Cell culture and viability assay 
Experiments were carried out on the highly tumorigenic p53 mutant epithelial subtype REN 
cell line, a widely used in vitro human mesothelioma model, originally isolated and 
characterized by Dr Albelda SM (University of Pennsylvania, Philadelphia, PA, USA; Bertino 
et al., 2008; Ranzato et al., 2011). The non-malignant human mesothelial cell line, MeT5A, 
was used as a normal control (Ke et al., 1989). Cells were cultured in DMEM supplemented 
with 10% fetal bovine serum and 1% penicillin-streptomycin solution.  
Cell viability and proliferation was determined by the calcein assay, carried out using the 
lipophilic calcein-acetoxymethylester (calcein-AM). Cells were settled in 96-well plates for 
24 h and then subjected to the specified treatments. Thereafter, plates were washed with PBS, 
incubated for 30 min at 37 °C with a solution of 2.5 µM calcein-AM in PBS, and then read in 
a fluorescence plate reader (Infinite 200 Pro, Tecan, Wien) by using 485 nm excitation and 
535 nm emission filters. 
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2.3 Intracellular calcium measurements 
Cytosolic Ca2+ concentration ([Ca2+]i) was measured by loading cells with the fluorescent 
Ca2+ chelator Fura-2 (Mazzolini et al., 2001; Marchetti et al., 2014), using a 
microspectrophotometry fluorescence-ratio setup equipped with a perfusion system. Cells 
were plated on poly-L-lysine coated glass coverslips and incubated with 10 µm Fura-2-
acetoxymethyl ester (Fura-2-AM, Molecular Probes™) in a physiological saline (see below), 
at 37 °C for 40 minutes. Then coverslips were washed and mounted on the stage of an 
inverted microscope (Axiovert Zeiss, Germany) where the cell monolayer was continually 
superfused by gravity flow (10 ml/min) and all modifiers were applied by bath solution 
exchange. Cells were illuminated by a xenon lamp through a wavelength selector 
monochromator; emission was observed through an X40 quartz objective and recorded by a 
photomultiplier. The ratio E340/E380 was calculated every 40 msec to acquire a time-
dependent, [Ca2+]i-sensitive signal. The physiological standard bath solution contained (in 
mM) NaCl 140, KCl 5.4, CaCl2 1.0, MgCl2 1.0, 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) 10, and glucose 10. The pH was adjusted at 7.4 with 
NaOH. The Ca free solution had the same composition with  0 CaCl2, 4 MgCl2 and 2 ethylene 
glycol-bis(2-aminoethylether)-N,N,N',N'-tetraacetic acid (EGTA).  [Ca2+]i  was calculated 
according to the function of Grynkiewicz et al., (1985). Parameters values were obtained at 
the end of each experiment by incubating the cells with 10µM ionomycin (Sigma-Aldrich) in 
Ca2+-free and standard Ca2+ solutions, as described previously (Marchetti et al., 1995; 
Mazzolini et al., 2001). All data are presented as [Ca2+]i , unless otherwise stated. 
2.4 Immunofluorescence 
Cells were fixed for 10 min at room temperature with 3.7% (w/v) para-formaldehyde in PBS, 
and permeabilized for 2 min with 0.1% Triton-X100. Blocking reaction was performed with a 
buffer containing 2% BSA-PBS for 1 h, at 37 °C. Cells were then washed twice with PBS and 
incubated with primary antibody anti Cav3.2 (clone S55-10 dilution 1:200, Novus 
Biologicals, Littleton, CO), followed by proper secondary antibody conjugated to Alexa 
Fluor® (dilution 1:200, Termo Fisher Scientific Waltham, MA USA). Both incubations were 
performed at room temperature for 1 h. Then, cells were incubated with fluorescein 
isothiocyanate (FITC)-labeled phalloidin (5 µg/mL) for 15 min at room temperature. Cells 
were visualized in a Nikon confocal system (Nikon Europe B.V.), equipped with Andor 
Revolution XD spinning-disk (Andor Technology Ltd, Belfast), Agilent laserbox with 405, 
488, 561 and 640 nm solid state laser, and Andor Ixon3 897 EMCCD camera. 
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2.5 RNA interference (siRNA) 
RNA interference was obtained by transfecting cells with 5 µM siRNA oligonucleotides (T-
type Ca2+ CP α1H siRNA (h): sc-42706, Santa Cruz Biotechnology, Dallas, TX) or with 
equimolar scramble siRNA, by using the N-ter Nanoparticle siRNA Transfection System 
(Sigma-Aldrich). Scramble siRNA was obtained using non-targeting siRNA (Control siRNA-
A: sc-37007, Santa Cruz Biotechnology). Experiments were performed 48h after transfection. 
2.6 Western blot 
Cell cultures were transferred on ice, rinsed twice with PBS (without Ca2+ and Mg2+) and 
lysed by incubation with 0.1 ml/well of RIPA buffer (150 mM NaCl, 1% NP-40, 0.5% 
sodium deoxycholate, 0.1% SDS, and 50 mM Tris, pH 8.0), supplemented with freshly added 
0.5 mM PMSF (phenyl-methylsulfonyl fluoride), for 30 min at 4 °C. Lysates were scraped 
from the dish, collected by centrifugation for 10 min at 10,000 g at 4 °C, and then 
supernatants were aliquoted and stored at -80 °C. The protein concentration was determined 
by Bicinchoninic Acid (BCA) Protein Assay (G-Biosciences®, Geno Technology Inc, St. 
Louis, MO), using bovine serum albumin as a standard. Amounts of 25 µg of protein were 
loaded on gel, subjected to SDS-PAGE (10% gel), and transferred to a nitrocellulose 
membrane, using a Bio-Rad Mini Trans Blot electrophoretic transfer unit (Bio-Rad 
Laboratories, Hercules, CA). Membrane was blocked for nonspecific protein with 5% non-fat 
dry milk in PBS for 30 min, and then probed at room temperature for 1 hour with primary 
antibody against Cav3.2 (clone S55-10, dilution 1:5000, Novus Biologicals, Littleton, CO), or 
against β-actin as equal loading control. Membrane was then washed three times (10 min per 
wash) with PBS supplemented with 0.05% Tween-20, to remove unbound antibodies, and 
further incubated with proper secondary antibody conjugated with anti-mouse horseradish 
peroxidase (dilution 1:5000; Cell Signaling Technology®, Life Science, Danvers, MS). 
Membrane was developed using an Amersham ECL chemiluminescence kit (GE Healthcare, 
Little Chalfont, UK) according to the manufacturer’s protocol, and digitized with Quantity 
One Image Software (ChemiDoc XRS, Bio-Rad).   
2.7 Statistics 
Data were analysed using Sigma Plot software (Systat Software Inc.). Data are shown as 
mean±sem, or mean±sd for proliferation assays. Statistical significance was evaluated by 
Student’s t-test or Man-Whitney Rank Sum test, as indicated by the software. The difference 
between two conditions was considered significant if p < 0.05. 
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3. Results 
3.1 Resveratrol fluorescence does not hinder Fura-2 measurements of [Ca2+]i 
at pharmacological doses. 
Resveratrol (Res) is a member of the stilbene family and, when stimulated by 340 nm light, 
emits fluorescence at 510 nm; thus its fluorophore spectral properties are remarkably similar 
to those of Fura2 and, in previous work, it has been claimed that Res is not compatible with a 
Fura2-based assay for measuring intracellular Ca2+ signaling (Kopp et al., 2013; Paudel et al., 
2014). Therefore, we undertook a series of tests to verify if it is possible to use Fura2 to 
measure intracellular Ca2+ levels in the presence of Res. First, we measured the Res 
fluorescence emission at 510 nm, following 340 nm excitation, in free solution and the dose-
response curve indicates that Res intrinsic fluorescence is negligible for concentration up to 
10 µM  (EC50 = 122 µM, Fig. 1A). Next, we examined the response to various concentrations 
of Res in Fura2-loaded cells with the microspectrophotometry system for Ca2+ measurements. 
In this case, cells were stimulated alternatively by 340 and 380 nm and emission was recorded 
again at 510 nm. When Res was added at a concentration of 100 and 400 µM, we recorded a 
steep increase in emitted fluorescence following 340 nm excitation, and a similar, smaller rise 
also with 380 nm excitation. This behavior indicates that the response was mainly due to Res 
intrinsic fluorescence, making it difficult to resolve the Fura2 Ca2+-dependent signal (Fig. 1-
B1). Yet, exposure of Fura2-loaded cells to 10 µM Res yielded fluorescence rise with 340 and 
fluorescence decrease with 380 nm excitation, indicating that in this case the fluorescent 
signal is almost completely due to Fura2 response to [Ca2+]i rise (Fig. 1-B2).  This 
concentration of Res (10 µM) caused a response that was qualitatively similar to that 
determined by treatment with thapsigargin, a well know Ca2+ mobilizer that blocks Ca2+-
ATPase and triggers release of Ca2+ from intracellular stores (fig. 1-B3). Hence, we 
concluded that as long as Res is used at concentrations ranging between 1 and 10 µM, the 
intrinsic Res fluorescence is negligible and measurements reflect the Ca2+-dependent Fura2 
response. Therefore, in subsequent experiments Res effects on [Ca2+]i were investigated only 
in this concentration range.  
 
3.2 Resveratrol caused a rise in [Ca2+]i in MPM REN cells due to 
extracellular Ca2+ entry.  
Fura-2-loaded REN cells were transiently exposed to 1-10 µM Res, showing dose-dependent 
peaks of [Ca2+]i (Fig. 1C). When Ca2+ was removed from the external solution and EGTA 
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added, Res did not caused any effect (Fig. 1D), indicating that the observed [Ca2+]i rise 
depends on the influx of external Ca2+. 
Previous findings on the same cells suggested the Ca2+ entry induced by Res can be linked to 
the activation of T-type Ca2+ channels and in particular the Cav3.2 isoform (Ranzato et al., 
2012).  Specific expression of Cav3.2 Ca2+ channels in REN cells was revealed by 
immunofluorescence coupled to confocal microscopy, suggesting a clustering of these 
channels in the plasma membrane (Fig. 2A). In addition, the Res-induced Ca2+ rise was 
significantly reduced by Ni2+ (30 µM), a low selective T-type Ca2+ channel blocker, as well as 
by the mibefradil analog NNC 55-0396 (5 µM) (Fig. 2B-D). The Ca
2+ 
peak was reversibly 
affected by Ni
2+ 
(30 µM), a low selective T-type Ca
2+ 
channel blocker, as well as by the 
nonhydrolyzable analog of mibefradil NNC 55-0396 (5 µM) that has a higher selectivity for 
T-type channels (Huang et al., 2004; Okubo et al., 2011). To assure reversibility, this drug 
was applied very briefly and only together with Res (fig.2C).  
3.3 Res-induced Ca2+ rise is mediated by the Cav3.2 T-type Ca2+ channel. 
Further evidence for the involvement T-type Ca2+ channels, and specifically of the Cav3.2 
channel protein, was obtained using siRNA knockdown targeting the human CACNA1H 
gene, which encodes for the α1H subunit of the Cav3.2 T-type Ca2+ channel. Western blot 
analysis confirmed the expression of this channel in wildtype cells, or in cells subjected to 
scramble siRNA, while specific siRNA abolished the expression of the channel protein (Fig. 
3A). Fura-2 measurements revealed that the Res induced [Ca2+]i spike was significantly 
reduced following Cav3.2 knockdown, whereas [Ca2+]i spike was retained in cells treated 
with scramble siRNA (Fig.3B,C). 
3.4 Res is more effective on REN cells than on normal mesothelium MeT5A 
cells. 
In order to evaluate the possible relevance of the Res effect on [Ca2+]i for therapeutic purpose, 
a comparison between REN cells and the non-malignant human mesothelial cell line MeT5A 
was made. Dose-dependent curves of Res-induced [Ca2+]i peaks showed a rightward shift for 
mesothelium (EC50 = 4.9 µM) with respect to mesothelioma (EC50 = 2.7 µM), indicating that 
tumor cells are more sensitive to the effect of Res on [Ca2+]i (Fig. 4A,B). 
Moreover, when REN cells were incubated for 7 days with 3 or 10 µM Res, proliferation was 
significantly inhibited, whereas Res was ineffective on proliferation of Met-5A cells, as 
illustrated by growth curves in Fig. 4C. 
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4. Discussion  
Resveratrol has been reported to interact with Ca2+ regulatory mechanisms in different cells 
and potential clinical relevance of these effects has been suggested (McCalley et al., 2014). In 
this study, we describe an effect of Res that is largely dependent on extracellular Ca2+ and is 
likely to involve specific Ca2+ channels. The effect of Res on voltage-dependent Ca2+ 
channels (VDCC) was reported in vascular myocytes (Campos-Toimil et al., 2007) and 
insulinoma cells (Jakab et al., 2008) and these channels were proposed to be involved in the 
vasorelaxant effect of Res in rat mesenteric artery (Gojkovic-Bukarica et al., 2008). In 
vascular myocytes, stimulation of Ca2+ influx, allegedly mediated by other Ca2+-permeable 
channels, was also reported (Campos-Toimil et al., 2007).  In cancer cells, previous studies 
showed that Res is able to induce elevations of [Ca2+]i that lead to compromised 
mitochondrial function and apoptosis (Ma et al., 2007; Sareen et al., 2007; Chang et al., 
2013).  
T-type Ca2+ channels have attracted attention as possible targets of anticancer treatments. 
These channels are abnormally expressed in various kinds of tumors and it has been 
hypothesized that their blockade may reduce cell proliferation and induce apoptosis (Taylor et 
al., 2008).  Following this view, in a series of studies the arrest of tumor cell growth has been 
achieved by using T-type Ca2+ channels inhibitors with different degrees of specificity 
(Bertolesi et al., 2002; Taylor et al., 2008; Li et al., 2011; Loughlin, 2014).  However, both 
proliferation and apoptosis are the result of an increase in intracellular Ca2+ (Lang and 
Stournaras, 2014). Proliferation is triggered by oscillating Ca2+ activity, while apoptosis by 
sustained Ca2+ entry caused by Ca2+ permeable cation channels (Berridge et al., 2003).  The 
experiments presented in this study suggest that this kind of role may be played by T-type 
Ca2+ channels in cancer cells. Given that these channels can be constitutionally open at resting 
membrane potential, they may drive a sustained Ca2+ influx in cells exposed to Res. Due to 
this window current, T-type Ca2+ channels have been linked to the occurrence of apoptosis, 
and a recent study has demonstrated that in human embryonic kidney HEK293 cells the 
expression of recombinant Cav3.2 T-type Ca2+ channels triggers apoptosis via mitochondrial 
pathways (Uchino et al., 2013). In another model, PC12 cells, the opening of Cav3.2 channels 
was shown to contribute to cytotoxic Ca2+ overload in the cytosol and in mitochondria 
(Gouriou et al., 2013).  
In the cancer cell model used in this study (malignant pleural mesothelioma REN cells), Res 
induced transient [Ca2+]i elevations that appear to occur through T-type Ca2+ channels. The 
experiments concentrated on the Cav3.2 isoform (containing the α1H subunit) because this 
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particular channel subtype has been shown to be highly expressed in REN cells, as well as in 
malignant pleural mesothelioma biopsies from patients, but not in normal mesothelium and in 
normal pleura. Moreover, in REN cells Cav3.2 siRNA has been previously found to reduce in 
vitro EGCG cytotoxicity (Ranzato et al., 2012). The immunofluorescence images presented 
here provide the first visual localization of these channels in this cell line. In addition, we 
identified the Cav3.2 T-type Ca2+ channel as the major responsible of Ca2+ entry in Res-
induced peaks. This was done by pharmacological inhibition first using Ni2+, which is 
considered a low specificity ionic blocker. However, high doses (mM range) of Ni2+ block all 
VDCC as well as other Ca2+-permeable channels (Marchetti and Gavazzo, 2012), but in the 
10 µM range, Cav3.2 is among the most sensitive to Ni2+ blocking (Lacinova et al., 2000), 
making the effect of this ion a significant preliminary test of Cav3.2 involvement. We also 
tested the mibefradil analog NNC 55-0396, a compound that displayed better specificity 
toward T-type Ca2+ channels with respect to L-type in HEK293 transfected with either α1G 
(Cav3.1; Huang et al., 2004) or α1H (Cav3.2) channel (Okubo et al., 2011). Finally, the role of 
Cav3.2 channel was confirmed by the ability of Cav3.2 siRNA to inhibit the effect of Res, in 
comparison with scramble siRNA (Fig.3). 
Although these observations clearly suggest an important role of Cav3.2 channel in the action 
of Res on [Ca2+]i in REN cells, the mechanism underlining this effect is still undetermined.  In 
a previous study, it was shown that EGCG-induced H2O2 release stimulates the opening of 
Cav3.2 channels (Ranzato et al., 2012). In another system (MCF7 breast cancer cells ) EGCG 
triggered the opening of T-type Ca2+ channels through K+ channel inhibition and subsequent 
membrane depolarization (Ranzato et al., 2014). However, so far we have no indication that 
Res operates through these mechanisms in REN cells, while it is possible that it directly acts 
on T-type Ca2+ channels as a positive modulator, as observed with EGCG in HEK293 cells 
exogenously expressing Cav3.2 (Ranzato et al., 2014). 
A significant relationship between the Res-induced [Ca2+]i increase and mesothelioma cell 
proliferation was obtained by comparing the effect observed on REN cells with that on 
normal mesothelial counterparts. At a dose of 3 µM Res, i.e. close to its EC50 on [Ca2+]i in 
REN cells, a sharp divergence was observed between the responses of cancer and normal 
cells. Also, in REN cells significantly higher alterations of [Ca2+]i were accompanied by cell 
growth inhibition in 7 day treatment, whereas in mesothelial cells negligible alterations of 
[Ca2+]i and cell growth were found. 
We have used malignant mesothelioma REN cells as cancer model cells. Pleural 
mesothelioma are rare cancers, associated with asbestos exposure (Roe and Stella, 2015), and 
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with still rising incidence rates worldwide (Stayner et al., 2013). The prognosis of these 
tumors is very poor and the treatment options are far from satisfactory, with no single 
modality therapy proven effective, presumably because of the multiplicity of survival and 
chemoresistance pathways (Heintz et al., 2010). For this and other severe forms of cancer, it 
is important to explore the possibility of combining more tolerated compounds with 
conventional drugs and devise synergistic treatments with reduced side effects. Along with 
their preventive action, a number of dietary phytochemicals, like vitamins and polyphenols, 
exhibit synergistic effects with chemotherapy and radiotherapy (Kampa et al., 2007). Previous 
studies from our laboratory have revealed a synergistic behavior of the drug gemcitabine in 
combination with ascorbate and EGCG (Volta et al., 2013).  
Our present findings demonstrate that Res-induced [Ca2+]i dysregulation in mesothelioma 
cells, through stimulation of T-type Ca2+ channels, occurs at low pharmacological 
concentrations. These doses could be achieved in clinical treatments and are likely to induce 
limited side effects (Patel et al., 2010). Therefore, Res seems a good candidate for the 
development of low-toxicity, combined chemotherapies together with more cytotoxic 
conventional antitumor drugs. 
 
5. Conclusion 
We have shown a previously unreported effect of Res on [Ca2+]i, using malignant 
mesothelioma cells in vitro as a cancer model. The effect consists in the induction of [Ca2+]i 
peaks involving the activity of Cav3.2 T-type Ca2+ channels. In contrast to present tendencies, 
our data suggest that it is possible to affect cancer cell growth by stimulating the activity of 
these channels, causing an influx of Ca2+ that may interfere with cell cycle progression, and 
be significant for apoptosis induction. The effect of Res appears to be dose-dependent within 
a pharmacologically achievable range, and these low concentrations are likely to induce 
limited side effects. Therefore, Res seems a candidate for the development of low-toxicity 
chemotherapies in combination with more cytotoxic conventional antitumor drugs. 
Accordingly, T-type Ca2+ channels are a possible new target in the therapy of mesothelioma, 
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Figure legends 
Fig. 1 –Resveratrol (Res) fluorescence does not hinder Fura-2 measurements of internal Ca2+ 
elevation at pharmacologically relevant doses. 
(A) Concentration-dependent curve of Res intrinsic fluorescence measured in cell-free 
solution with Ex 340 nm and Em 510 nm (bandwidth 20 nm). Fluorescent values (F, relative 
arbitrary units) were normalized to the value in the absence of Res (F0). The dose-response 
curve displayed EC50 = 122 µM.  
(B) Time-course of 510 nm fluorescence (in relative fluorescent units, RFU) recorded 
following 340 and 380 nm Ex in Fura-2-loaded REN cells exposed to 100 and 400 µM Res 
(B1), to 10 µM Res (B2), and to 1 µM thapsigargin in Ca2+-free solution (B3). The lower 
graphs represent the time course of the ratio F340/F380, in each case. The higher doses of Res 
caused an increase of fluorescence with both 340 and 380 nm excitations; the ratio, 
F340/F380, increased steeply as soon as Res was applied (B1). In contrast, the lower dose of 
Res (B2), as well as thapsigargin (B3), caused a fluorescence rise with 340 nm excitation and 
a decrease with 380 nm excitation, indicating a specific response of the Ca2+ sensitive dye, as 
also revealed by the ratio time course. (C) Intracellular Ca2+ peaks following stimulation with 
1, 3, 10 µM Res in Fura-2-loaded REN cells. Treatments are marked by bars under the traces. 
[Ca2+]i  was calculated from the parameter values obtained at the end of each experiment by 
incubation of the cells in 10µM ionomycin in Ca2+-free and standard Ca2+ solutions. (D) 
Stimulation with 10 µM Res did not elicit Ca2+ rise in Fura2-loaded REN cells when Ca2+ was 
removed from the bath (0 Ca), but the response was restored when Ca2+ was added again. 
This observation indicates that the effect of Res is dependent on external Ca2+. 
 
Fig. 2 - Resveratrol driven elevation of intracellular Ca2+ in Ren cells is dependent on the 
activity of T-type Ca2+ channels. 
(A) Immunofluorescence imaging of REN cell monolayer labelled with primary antibody 
anti-Cav3.2, followed by Alexa fluor 594-secondary antibody (red; left picture), and without 
primary antibody (right picture). In both cases, FITC-phalloidin counterstain (green) is 
present. Red staining reveals the distribution of Cav3.2 protein channels (left), suggesting 
channel clustering in the plasma membrane. Cells hybridized only with secondary antibody 
show negligible red fluorescence (right). (B) Treatments with 30 µM Ni2+ or (C) with 5 µM 
NNC 55-0396 (marked by bars under the traces) reversibly reduce the internal Ca2+ elevation 
induced by 10 µM Res in Fura-2-loaded REN cells. (D) Summary of the above effects in 
different (n=4) experiments. * indicates p<0.05 with respect to control. 
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Fig. 3 – Cav3.2 silencing reduces Res-induced Ca2+ peaks. 
 (A) Western immunoblot analysis of cell lysates showing expression of Cav3.2 protein in 
REN cells and Cav3.2 down-regulation by specific RNA interference (siRNA). REN cells 
were transfected or not (control) with negative control siRNA (scramble) or specific Cav3.2 
siRNA and results were recorded after 48 hr. (B) Fluorescent measurement of internal Ca2+ 
peaks following Res application to REN cells 48h after transfection with scramble or specific 
Cav3.2 siRNA. (C) Summary of the results in 5-9 different experiments. * = p<0.05 with 
respect to scramble. 
 
Fig. 4. The effect of Res on intracellular Ca2+ is more pronounced in REN cells than in 
normal mesothelium MeT5A cells.  
(A) Comparison of Ca2+ elevations following stimulation with increasing doses (1, 3, 5, 10 
µM) of Res in Fura-2-loaded REN cells (left) and normal mesothelium Met5A cells (right). 
(B) Dose dependence of [Ca2+]i variations induced by Res in MPM REN cells and normal 
mesothelium MeT-5A cells. Data are means±sem of peak values normalized as 
Δ[Ca2+]/basal[Ca2+]. Experimental points were approximated by the function: 
 
Δ[Ca2+]/basal[Ca2+] = A/(1+(EC50/x)n) 
 
where x is Res concentration. The best fit yielded A = (Δ[Ca2+]/basal[Ca2+])max = 3 for both 
cell types, EC50 = 2.7 µM, n= 1.7, for MPM REN cells, and EC50 = 4.9 µM, n = 3.5, for 
Met5A cells.  
(C). Growth curves obtained by calcein-AM cell density assay for REN (left) and MeT-5A 
(right) cells, incubated with 0, 3, and 10 µM Res for 1-7 days. Data are means±sd (n=16) of 
cell densities, normalized to the initial and maximum value in control (0 Res) condition. * = 
p<0.05 with respect to control.  
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Conclusions 
MPM is an aggressive cancer, with a poor prognosis and an increasing incidence as a result of 
widespread exposure to asbestos. Despite the implementation of various therapeutic 
approaches, the response rates to treatment are generally very low and the need to improve 
therapies is urgent. Surgery and radiotherapy have a limited role in highly selected patients 
and systemic therapy is the only potential treatment option for the majority of patients. 
Among alternative remedies for cancer treatment, there is a growing interest in the anticancer 
action of natural substances. 
In this study we have highlighted a novel mechanism of action for oleuropein, and its 
metabolite hydroxytyrosol.  
We have developed a method for obtaining olive leaf extract enriched in oleuropein, 
involving raw extraction, extract partitioning, and chromatographic separation. 
Treatments with oleuropein-enriched, leaf extract fraction, and its major component 
oleuropein induce [Ca2+]i rises in mesothelioma REN cells followed by a prompt recovery of 
the baseline level upon washout. These data indicate that the observed [Ca2+]i spikes are not 
due to cell membrane injury but rather depend on the influx of Ca2+ through membrane Ca2+ 
channels. Removal of Ca2+ from the external solution almost inhibits oleuropein effect and 
the use of the T-type Ca2+ channel inhibitor NNC-55-0396 reversibly reduces the Ca2+ spike 
suggesting at least a partial involvement of T-type Ca2+ channels. Hydroxytyrosol is more 
powerful than oleuropein in inducing Ca2+ spikes. Similar to the oleuropein fraction, 
increasing doses of standard oleuropein induce dose-dependent [Ca2+]i spikes but the 
cytotoxic effect of the oleuropein fraction is slightly, but not significantly, stronger than that 
of standard oleuropein. This kind of effect suggests a possible use of the oleuropein fraction 
from olive leaves in the treatment of mesothelioma (156). 
In this study we have also evaluated the pharmacological potentials of the grapes stilbene 
resveratrol.  
The effect of Res on MPM REN cells was studied by means of microspectrophotometry 
microscopy after cell loading with the fluorescent probe fura-2. Resveratrol shows 
autofluorescence that may affect Ca2+ measurements but this intrinsic aspect of Res does not 
hinder Fura-2 measurements of [Ca2+]i at pharmacological doses. 
	   86 
Cells transiently exposed to 1, 3, or 10µM Res show increasing peaks of [Ca2+]i.  No effect is 
visible in Ca2+-free medium, while the [Ca2+]i peak is reduced by non-selective (Ni2+) and 
highly selective (NNC 55-0396) T-type Ca2+ channel blockers. Dose-dependent curves of 
Res-induced [Ca2+]i peaks show a rightward shift for normal MeT-5A mesothelial cells (EC50 
= 4.9 µM) with respect to MPM REN cells (EC50 = 2.7 µM), indicating higher sensitivity of 
tumor cells to Res. Accordingly, incubation with 3 or 10µM Res for 7 days resulted in cell 
growth inhibition for REN cells but not for mesothelial cells. The effect shows selectivity 
towards MPM cells, suggesting its possible use in the clinical treatment of mesothelioma 
malignancies.  The complex of data indicates that Res induces a Ca2+ influx that is possibly 
mediated by T-type Ca2+channels and in particular the Cav3.2 isoform. Specific expression of 
Cav3.2 Ca2+ channels in REN cells was revealed by immunofluorescence coupled to confocal 
microscopy, suggesting a clustering of these channels in the plasma membrane. Cav3.2 gene 
silencing by siRNA abolishes the expression of Cav3.2 channel and reduces the effect of 
resveratrol on Ca2+ (157). 
The complex of data shows that various polyphenols, such as oleuropein, hydroxythyrosol 
and resveratrol, are able to induce non-physiological Ca2+ dynamics in mesothelioma cells, 
involving T-type Ca2+ channels. Data also show that such a disturbance affect MPM cell 
growth rates, possibly interfering with tumor development, and suggesting T-type Ca2+ 
channels as possible therapeutic targets. Also, the effect occurs at low pharmacological 
concentrations, possibly inducing limited side effects. Therefore, these polyphenols are 
possible candidates for the development of low-toxicity chemotherapies to be used as 
synergistic agents in combination with more cytotoxic conventional antitumor drugs (158). 
In conclusion, the results of the present study are consistent with the increasing interest for 
natural compounds with antitumor properties, suggesting a promising future for this kind of 
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